

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 December 2004 (09.12.2004)

PCT

(10) International Publication Number
WO 2004/105573 A2

- (51) International Patent Classification⁷: **A61B**
- (21) International Application Number:
PCT/US2004/014521
- (22) International Filing Date: 21 May 2004 (21.05.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/472,173 21 May 2003 (21.05.2003) US
60/506,042 25 September 2003 (25.09.2003) US
- (71) Applicant (*for all designated States except US*): THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY [US/US]; 3601 Spruce Street, Philadelphia, PA 19104 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): SHOWE, Louise, C. [US/US]; 95 Indian Spring Road, Media, PA 19063 (US). SHOWE, Michael, K. [US/US]; 95 Indian Spring Road, Media, PA 19063 (US). KARI, Laszlo [HU/US]; 873 N. 23rd Street, Philadelphia, PA 19130 (US). NEBOZHYN, Michael [UA/US]; 800 Laurel Road, Yeadon, PA 19050 (US). LOBODA, Andrey [UA/US]; 2501 Pennsylvania Avenue, Apt. #531, Philadelphia, PA 19130 (US).
- (74) Agents: BAK, Mary, E. et al.; Howson and Howson, 321 Norristown Road, Suite 200, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHOD OF DIAGNOSIS OF CANCER BASED ON GENE EXPRESSION PROFILES IN CELLS

(57) Abstract: A method of developing a gene expression profile indicative of the presence or stage of a selected disease, disorder or genetic pathology in a mammalian subject employs penalized discriminant analysis with recursive feature elimination. A method of diagnosing a cancer in a mammalian subject includes the steps of examining a sample containing the subject's immune cells and detecting a variance in the expression of a statistically significant number of genes, e.g., at least 10 non-tumor genes from those same genes in a characteristic disease or healthy gene expression profile. A significant variance in expression of these genes when compared to a gene expression profile, preferably an average gene expression profile of a normal control, or significant similarities to an average gene profile of subjects with cancer, correlates with a specific type of cancer and/or location of tumor.

WO 2004/105573 A2

METHOD OF DIAGNOSIS OF CANCER BASED ON GENE EXPRESSION
PROFILES IN CELLS

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
5 DEVELOPMENT

This invention was supported in part by the Grant Nos. UO1-CA85060 and P30 CA10815-34S3 from the National Institutes of Health. The United States government has an interest in this invention.

10 BACKGROUND OF THE INVENTION

The present invention relates to the diagnosis of cancer, and more specifically to the use of characteristic patterns of gene expression by circulating cells of the immune system and/or circulating cancer cells and/or tumor cells as a method of diagnosis.

15 Microarrays of several different types have been used to characterize cancer types in patients, most often to distinguish the tissue of origin or a tumor (Ramaswami *et al.*, 2001, *Proc. Natl. Acad. Sci. USA*, 98:15149-54) or original cell type of a leukemia (Golub *et al.*, 1999 *Science*, 218:531-7). In contrast, current practice of cancer diagnosis usually depends on imaging methods, e.g., chest X-rays, histological studies, mammograms, and the like. More recently efforts have been made to detect proteins
20 characteristic of certain cancers in serum, e.g., PSA for prostate cancer.

cDNA arrays have been used to characterize the components of the immune system, as purified cells (Hamalainen, H., *et al.* 2001 *Genome Biol* 2: RES.0022), as cell lines, as mixtures of peripheral blood mononuclear cells (PBMC) (Alizadeh, A.A., and L.M. Staudt, 2000 *Curr Opin Immunol* 12:219-2255), and in whole blood
25 (Whitney, A.R., *et al.*, 2003 *Proc Natl Acad Sci U S A* 100:1896-19016). However most attempts to describe the immune response to cancer, especially tumors, has made use of monoclonal antibodies to characterize the type and differentiation state of B-cells, T-cells, natural killer (NK) cells and dendritic cells, which infiltrate tumors. The reflection of this infiltration is observed by activated cells in the peripheral blood. See,
30 e.g., Fracchia, A., *et al.*, 1987 *Respiration* 51:161-169; Domagala-Kulawik, J., *et al.*, 2001 *Diagn. Cytopathol.*, 25:208-213; Mazzocchi, G., *et al.* 1999. *In Vivo* 13:205-209; and Lee, P.P. *et al.*, 1999 *Nat Med* 5:677-6850.

A number of microarray studies have identified genes that appear to be useful for diagnosis of a variety of different cancers. Changes in individual gene products have been reported on tumor infiltrating lymphocytes (TILs) and peripheral blood mononuclear cells (PBMCs) from cancer patients. For example, the loss in colorectal adenocarcinoma patients of the Zeta (signal transducing) chain of the TCR/CD3 complex of T-cells in a tumor-stage specific manner from both TILs and PBLs was reported (Choi, S.H., *et al.*, 1998 *Cancer Immunol Immunother* 45:299-305). The Zeta-associated kinase, p59 fyn, was also reduced in PBMC from patients relative to controls. Numerous receptors have been shown to function in targeting lymphocytes either to skin, on the one hand, or various mucosa on the other. These include the cutaneous lymphocyte antigen (CLA) and chemokine receptors CCR4 and CCR10/CTACK expressed on skin-homing lymphocytes, the integrin $\alpha 4 \beta 7$ which directs homing to the gastric mucosa, and integrin $\alpha 4 \beta 1$ expressed on lymphocytes which are directed to non-intestinal mucosa such as those of the lungs (see, e.g., Kunkel, E.J., and E.C. Butcher. 2000 *Immunity* 16:1-4). In addition to these T-cell gene products, B-cells have been reported to express different heavy chains depending on their target tissue. NK T-cells, which are associated with the IL-12 dependent rejection of some tumors (Cui, J., *et al.* 1997 *Science* 278:1623-16263) express different sets of Va and Vb T-cell receptor chains that are associated with homing to different lymphoid organs (e.g. bone marrow, liver, spleen (Eberle, J., *et al.* 1999 *J Invest Dermatol* 112:925-9324).

Few of these above-noted microarray studies translate the results to assays suitable for clinical use. For example, a "gene expression ratio" method differentiates patients with mesotheliomas from adenocarcinomas of the lung by using simple ratios of pairs of expressed genes determined by PCR (Gordon, G. J., *et al.* 2002 *Cancer Res*, 62: 4963-4967). This method is dependent on being able to identify gene pairs whose differences in expression levels are very highly significant between the 2 tumor types being compared. These types of differences might be expected where the organ or cell-type of tumor origin are different.

Cutaneous T-cell Lymphoma (CTCL), the most common of the T-cell lymphomas, is a non-Hodgkin lymphoma of epidermotropic lymphocytes. Approximately 1500-2000 new cases are reported in the United States each year.

Causative roles in the development of CTCL have been suggested for various environmental factors and infectious agents, but the etiology of the disease remains unknown (Li, G et al, *J. Invest. Dermatol.*, 107:308-313; Kim, Y.H., and R.T. Hoppe. 1999 *Semin Oncol*, 26:276-289). CTCL is characterized by the accumulation of malignant cells with a low mitotic index, suggesting that the regulatory defect allowing these cells to accumulate may reside in the apoptotic pathways (Dereure, O., et al, 2000 *Brit. J. Dermatol.* 143:1205-1210; Edelson, R.L. 2001 *Ann N Y Acad Sci* 941:1-11). Mycosis fungoides (MF) and Sezary syndrome (SzS) are the two major clinical variants of CTCL (Kim, Y. H. and Hoppe, R. T. 1999 *Semin Oncol*, 26: 276-289 (Kim III); Kim, Y. H. et al, 1996 *Arch. Dermatol.*, 132: 1309-1313 (Kim II); and Diamandidou, E. et al. 1996 *Blood*, 88: 2385-2409).

MF is skin associated and progresses through increasing cutaneous, and finally organ involvement. Although treatable in early stages, MF is frequently misdiagnosed because of similarities to more benign forms of skin disease. Even with early diagnosis, 10% of MF patients who present with limited disease and about 25% of those with extensive patches or plaques will develop progressive disease, eventually succumbing despite extensive therapy (Kim I; Kim, et al 1999 *Arch Dermatol* 135:26-32 (Kim IV). SzS, a leukemic and erythrodermic variant of CTCL, is characterized by the presence of circulating lymphocytes with atypical cerebriform nuclei (Sezary cells) in the skin, lymph nodes, and peripheral blood. It is a more aggressive form of CTCL, which is associated with a poor prognosis and with a mean survival of three years from the time of diagnosis. Immunophenotyping and genotyping of Sezary cells indicates that they arise as a clonal expansion of mature helper memory T-cells (Dereure, cited above and Edelson, cited above). They express cytokines characteristic of T-helper type 2 (Th2) cells, including IL-4, IL-5, and IL-10 (Dummer, R., et al, 1996 *Blood* 88:1383-1389; Nickoloff, B.J., et al, 1994 *Clin Immunol Immunopathol* 73:63-68; Rook, A.H., et al 1993 *Arch Dermatol* 129:486-489) and fail to express Th-1 cytokines, IL12, and IFN- γ (Vowels, B.R., et al., 1994 *J Invest Dermatol* 103:669-673). Patients with MF can have blood findings typically observed in SzS, and in rare cases MF can evolve into SzS, confirming a close relationship between the two conditions.

In both MF and SzS, early detection and treatment is directly correlated with outcome (Duvic, M. *Clin Lymphoma*, 1 Suppl 1: S15-20, 2000; Foss, F. M. 1 Suppl 1:

S9-14, 2000; Kim, Y. H. et al, *Arch Dermatol*, 131: 10031008, 1995 (Kim I).

However, although CTCL is readily treatable in early stages, this relatively rare cancer can be difficult to diagnose because of similarities to a variety of benign skin diseases and frequently goes undetected for years. Therapies using biological response
5 modifiers, such as extra-corporeal photopheresis and IFN- α , have improved survival of patients with SzS (Rook, A.H et al, 1999 *J Investig Dermatol Symp Proc* 4:85-90; Gottlieb, S.L et al., 1996 *J Am Acad Dermatol* 35:946-957). However, 50% of patients who present with advanced disease do not respond to therapy and 25% of those that respond initially will relapse and progress to fatal disease. There are presently no well-
10 defined clinical markers for CTCL that permit an early identification of patients most likely to develop progressive disease.

There remains a need in the art for novel methods using gene expression as a useful diagnostic method for cancer, and in particular, for a more efficient and inexpensive method for detecting the presence of cancer in a normal population for
15 purposes of screening, as a replacement for diagnostic imaging.

SUMMARY OF THE INVENTION

The present invention meets the need in the art, because it relates to the detection of cancer in a subject, e.g., a nominally healthy subject, to staging of cancer
20 in a subject with advanced disease, and/or to determination of the tissue or origin of such a cancer, and more specifically to the use of characteristic patterns of gene expression by cells as a method of diagnosis.

In one aspect, the invention provides a method of developing a gene expression profile indicative of the presence or stage of a selected a disease, disorder or genetic
25 pathology in a mammalian subject. The method involves the analysis of an array of gene expression levels from a biological sample of one or more subjects having the disease in question by applying penalized discriminant analysis and recursive feature elimination steps to the array. A gene expression profile is thereby obtained that is a characteristic of the selected disease, disorder or genetic pathology or a stage of the
30 selected disease, disorder or genetic pathology. The characteristic profiles may then be used in individual patient diagnostic assays.

In another aspect, the invention provides a method of diagnosing a disease, disorder or pathology, such as a cancer characterized by a solid tumor, and/or monitoring the effect of treatment of such cancer, in a mammalian subject. This method involves examining a biological, e.g., peripheral blood, sample containing circulating immune cells or cancer cells of the subject and obtaining a first profile of a plurality of genes and comparing same to a gene expression profile, such as described above for certain cancers, and/or to a second profile of the genes from a healthy subject or from a subject with another disease. In another aspect, the invention provides a method of diagnosing a cancer characterized by circulating cancer cells and/or monitoring the effect of such cancer treatment in a mammalian subject. This method involves examining a sample containing circulating cancer cells or tumor cells of the subject and detecting a characteristic profile of variance in the expression of a statistically significant number of genes using the steps described above. Variance in expression of these genes compared to expression of the same genes in a normal control correlates with the type and/or location of the cancer.

In another aspect, the invention provides a method of identifying the effects of a therapeutic agent or regimen on a patient having a cancer, such as described above. The method comprises administering the therapeutic agent or treatment regimen to the patient. Periodically during and after administration of the agent or regimen to the patient, another sample containing immune cells and/or circulating cancer or tumor cells of the patient is examined using the steps described above and arrays are prepared of genes that are then compared to a characteristic expression profile for that disease or stage of disease/therapy. The patient's expression profile can also be then compared to the same profile obtained from the patient prior to the administration. Optionally, the current expression profile is compared to a control profile from a healthy subject. Detection of a variance in expression of the genes in the current profile from the prior profile or from the normal control indicates the level of efficacy of the agent or regimen.

In yet another aspect, the invention provides a method of identifying a cancer therapeutic agent or regimen useful for the treatment of a cancer. This screening method comprises the steps of administering the therapeutic agent or treatment regimen to a test mammalian subject. Periodically during and after administration of the agent

or regimen, another sample containing immune cells and/or cancer cells of the subject is examined using the steps described above and a current expression profile of a statistically significant number of genes is obtained. The current profile is compared to gene expression profiles for that disease or stages or that disease, as well as to the same profile obtained from the subject prior to the administration and optionally to a control profile from a healthy subject. Detection of a variance in expression of the genes in the current profile from the prior profile and to the characteristic profile, which variance is closer to the profile of the normal control, indicates that the agent or regimen is a desirable cancer therapeutic for the cancer.

In still another aspect, the invention provides a method for determining the response of an individual patient to a therapeutic agent or regimen by employing the above-described methods.

In still further aspects of this invention, certain gene profiles characteristic of certain diseases are provided.

In yet a further aspect, the invention provides a method for diagnosing, staging or monitoring a cutaneous T cell lymphoma (CTCL). This method involves detecting in a biological sample, e.g., peripheral blood, the level of one or more significant genes, which exhibit variant expression from its expression in a normal sample. In one embodiment, this aspect involves detecting the variant expression of at least two of five specific genes. In another embodiment, the method involves detecting the variant expression of five specific genes. In still additional embodiments, this method of the invention involves detecting variant expression of 10 or more than 10 variant genes from their respective expression in a normal sample.

In yet another aspect, the invention provides a non-naturally occurring or purified ligand that binds to plastin tissue protein (PL3) within one of two specifically identified epitope sequences. In one embodiment, the ligand is an antibody. In another embodiment, the ligand is associated with a detectable label or label system.

In still another aspect, the invention provides a method for diagnosing CTCL in a sample comprising contacting said sample with a ligand of PLS3 and detecting the presence of the ligand in the sample.

In yet a further aspect, the invention provides a kit for diagnosis of CTCL in a mammalian patient comprising a ligand of plastin T and a detectable label or label system

Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A is a graph showing genes differentially expressed by t-test in PBMC from SzS patients compared to Th2 controls. Significant genes (SG) were detected at each p-value. False positives (FP) were estimated by permuting the sample labels 10,000 times (SG-FP). Estimates of the number of true positives are indicated by TP. The "true positive" curve attains a maximum value of 1000, suggesting that a significant number of differentially expressed genes are present at p-values > 0.01 . The number of missed genes, (MG, defined as $1000 - TP$) is less than 100 at $p = 0.10$.

FIG. 1B is a graph showing the number of observed significant genes corrected by the maximum number of significant genes found in permuted data as a function of p-value cutoff and percentile of the permutations.

FIG 2A is the top portion of a treeview showing the variation in expression of the 135 $p < 0.01$ significant genes that are either upregulated (black squares) or downregulated (white squares) > 2 -fold in eighteen high tumor CTCL burden patients as compared to nine Th2-skewed controls. The pale cluster identifies genes which are downregulated and the dark cluster genes which are upregulated in patients versus controls. Gray squares show variation between up and down-regulation. Values for fold increases or decreases (-) precede the gene symbols.

FIG. 2B is the lower portion of the treeview of FIG. 2A.

FIG. 3 is a bar graph showing the cross-validation of high SzS patients and normal controls by PDA, using all the genes on HA01-HA03 gene arrays (The Wistar Institute, Philadelphia, PA). Positive scores indicate patients. The accuracy of cross validation is 100%.

FIG. 4A is the top portion of a treeview showing the 90 best classifiers (e.g., most informative genes) that discriminate high Sezary patients from normal controls. Patient labels (e.g., S1134, etc.), and Th2 controls (e.g., C0032, etc) are listed above

the treeview. Genes are listed to the right of the treeview of FIG. 4. The symbols are as described for FIG. 2A.

FIG. 4B is the lower portion of the treeview of FIG. 4A.

FIG. 5 is a bar graph showing classification of 27 low tumor burden CTCL patients and 14 controls with 40 genes (PBMC=untreated). Negative values indicate the expression profiles that define the negative or control class and positive values identify samples assigned to the positive or patient class. The height of the columns measure how well each samples is classified by the list of 40 genes. Percent Sezary cells are indicated for each sample.

FIG. 6 is a graph showing the distribution of the number of clusters of genes in patients that correlate with an average expression profile calculated for each of 1065 $p < 0.1$ genes: closed symbols, observed expression values; open symbols, permuted expression values; circles, 50th percentile of observations; triangles, 95th percentile of observations.

FIG. 7 is a TreeView dendrogram showing the 38 genes with highest predictive power (i.e., whose expression levels best distinguish short-term (ST) from long-term (LT) CTCL survivors and the high tumor burden patients that they classify). The genes listed on the right-hand side are listed in order from most overexpressed in LT survivors at the top of the list to least expressed at the bottom of the list.

FIG. 8 is a bar graph showing classification of short term (ST), midterm (MT) and long term (LT) surviving CTCL patients using all 2032 genes in the HA03 data set (The Wistar Institute, Philadelphia, PA). Eleven ST and 25 LT survivors were used for training. Positive scores indicate classifications as ST patients and negative scores indicate classifications as LT patients.

FIG. 9A is a bar graph showing the classification of CTCL and control samples using 5 genes based on microarray data from high-tumor burden patients. Positive predictive scores denote patients (clear bars), negative scores denote controls (grey bars). This graph shows the leave-one-out cross-validation of the training set.

FIG. 9B is a bar graph showing the classification of CTCL and control samples using 5 genes based on validations on microarray data from low tumor burden patients. The labels on the X-axis are individual (S) samples and (C) controls. This graph shows the results of classifying the corresponding validation set.

FIG. 9C is a bar graph showing the classification of CTCL samples and controls using 5 genes based on qPCR data from aRNA of high tumor burden patients. Positive predictive scores denote patients (clear bars), negative scores denote controls (grey bars). This graph shows the leave-one-out cross-validation of the training set.

5 FIG. 9D is a bar graph showing the classification of CTCL and control samples using 5 genes based on validations by qPCR on aRNA from low tumor burden patients. This graph shows the results of classifying the corresponding validation set.

10 FIG. 9E is a bar graph showing the classification of CTCL and control samples using 5 genes based on qPCR data from total RNA of high tumor burden patients. Positive predictive scores denote patients (clear bars), negative scores denote controls (grey bars). This graph shows the leave-one-out cross-validation of the training set.

FIG. 9F is a bar graph showing the classification of CTCL and control samples using 5 genes based on validations on qPCR from total RNA for the blinded set. This graph shows the results of classifying the corresponding validation set.

15 FIG. 10 is a graph depicting gene expression in patient peripheral blood mononuclear cells (PBMC) samples from Example 7. Each patient or control corresponds with two bars. Each individual is indicated as a control (i.e., by a label beginning with C, e.g., C004 or with a V (volunteer), e.g., v3) or a cancer patient. Each cancer patient is identified by cancer type (e.g., adrenal), or by cancer type and number (e.g., NSCLC-4). The most distant samples from the same group are closer than the closest samples from different groups. The clear bars represent the maximum distance to a sample from an individual group. The dark bars represent the minimum distance to a sample from the other group. The most distant samples from the same group are closer than the closest samples from different groups, thereby indicating that this
20 particular gene set can distinguish these different types of samples. Thus, the patients
25 are more similar to each other than to any control.

FIG. 11 is a bar graph showing the relative changes in patient's PBMC as determined by the projection on the Control-Cancer Axis for patient samples as described in Example 7.

30 FIG. 12 is a bar graph showing predictive scores for four groups of samples: two groups of controls and two groups of cancers. Predictive scores were generated

by Penalized Discriminant Analysis (PDA), which used Control-1 and Lung Cancer groups for training.

FIG. 13 is a treeview cluster diagram showing unsupervised hierarchical clustering of patients and controls using genes with known functions in NK cells and cytotoxic (CD8) lymphocytes. Individual patients are represented as column headings along the top of the diagram. Genes forming the profile are indicated as row labels.

FIG. 14 is a bar graph depicting the results of cross-validation with PDA between Lung Cancer groups (first 10 bars from the Y-axis) and Mixed Cancer groups (last 9 bars from the Y-axis). The predictive score for each sample was obtained by setting this sample aside and using the rest of the samples for training.

FIG. 15 is a bar graph showing that changes in immune gene expression of each sample are relative to the difference between the average patient and average control. Individual patients are represented along the X-axis as described in FIG. 10. The bars labeled v1 to v9 are one group of control patients. The bars labeled C004 and C026-C030 are a second control group. The bars labeled NSCLC to NSCLC-9 are a lung cancer group. The bars labeled with different cancers represent a Mixed Cancer group.

FIG. 16 is a bar graph showing predictive scores for five groups of samples: two control groups and three groups of cancers. Predictive scores were generated by PDA. PDA was trained to distinguish PBMC from lung cancers from PBMC from the tumor controls. The entire dataset was then classified. All of the training samples were properly classified; all of the mixed solid tumors were classified as cancers and the CTCL controls (control-2) samples were classified as controls. The CTCL patient PMBC were classified as controls. PDA clearly distinguishes solid tumor patients from controls, but does not recognize the CTCL samples, which were not part of the training set, as distinct from controls.

DETAILED DESCRIPTION OF THE INVENTION

The present invention answers the need in the art by providing novel methods for diagnosis of cancers based on gene expression profiling.

In one embodiment, the invention provides a method of developing a gene expression profile indicative of the presence or stage of a selected disease, disorder or genetic pathology in a mammalian subject. The method involves the analysis of an

array of gene expression levels from a biological sample of one or more subjects having the disease in question by applying penalized discriminant analysis and recursive feature elimination steps to the array. The recursive feature elimination identifies and eliminates the least informative up-regulated and down-regulated genes from the first
5 profile. These steps are optionally repeated until a gene expression profile is obtained containing statistically significant number of genes that vary in expression from the expression of the same genes in the array of the healthy or disease control. This gene expression profile is a characteristic of the selected disease, disorder or genetic pathology or a stage of the selected disease, disorder or genetic pathology. The profile
10 of variance in expression of the genes compared to a normal control or to a disease control correlates with the type and/or location of the disease, disorder or genetic pathology. For example, variance in expression of these genes compared to expression of the same genes in a normal control correlates with the type and/or location of the cancer. One such cancer is cutaneous T cell lymphoma (CTCL). This characteristic
15 profile may then be used in individual patient diagnostic assays.

In one embodiment according to this method, the gene expression profiles of the immune cells circulating in the peripheral blood of cancer patients reflect the presence of a solid tumor. Preferably, for cancers characterized by solid tumors, the genes examined for the profiles are genes normally expressed by the patients' immune cells.
20 For cancers in which the tumor or cancer cells circulate in the peripheral blood, e.g., CTCL, the genes examined from the profiles are genes on the cancer or tumor cells themselves. Each profile is sufficiently specific to indicate the type and location of the cancer or tumor. In some embodiments, this characteristic gene expression is detectable earlier than any other sign of tumor presence. Gene expression profiling of peripheral
25 blood samples thus is a powerful tool for cancer diagnosis and staging, as well as the monitoring of therapeutic efficacy.

A. Definitions

"Patient" or "subject" as used herein means a mammalian animal, including a human, a veterinary or farm animal, a domestic animal or pet, and animals normally
30 used for clinical research.

"Sample" as used herein means any biological fluid or tissue that contains immune cells and/or cancer cells. A suitable sample for use in this invention, whether

the cancer is a solid tumor cancer or a cancer characterized by circulating cancer cells, includes peripheral blood. Other useful biological samples include, without limitation, whole blood, saliva, urine, synovial fluid, bone marrow, cerebrospinal fluid, vaginal mucus, cervical mucus, nasal secretions, sputum, semen, amniotic fluid, bronchoalveolar lavage fluid, and other cellular exudates from a patient having cancer. Such samples may further be diluted with saline, buffer or a physiologically acceptable diluent. Alternatively, such samples are concentrated by conventional means.

"Immune cells" as used herein means B-lymphocytes, T-lymphocytes, NK cells, macrophages, mast cells, monocytes and dendritic cells.

As used herein, the term "cancer" means any cancer. In one embodiment, the cancer is characterized by the presence of a solid tumor. Among such cancers are included, without limitation, breast cancer, neuronal cancer, prostate cancer, pancreatic cancer, brain cancer, melanoma, other skin cancers, esophageal cancer, colorectal cancer, ovarian cancer, small cell carcinoma, adrenal cancer, lung adenocarcinoma, mesothelioma, Hodgkins lymphoma and non-Hodgkins lymphoma without blood involvement. In another embodiment, the cancer is characterized by the presence of circulating cancer cells in the peripheral blood, e.g., CTCL, T-ALL, B-ALL, CML, CLL, APL, AML, B-CLL, or hairy cell leukemia. Suitable cancers for diagnosis or screening with the methods described below include early stage cancers or late stage cancers.

By "therapeutic reagent" or "regimen" is meant any type of treatment employed in the treatment of cancers with or without solid tumors, including, without limitation, chemotherapeutic pharmaceuticals, biological response modifiers, radiation, diet, vitamin therapy, hormone therapies, gene therapy, etc.

By "non-tumor genes" as used herein is meant genes which are normally expressed in other cells, preferably immune cells, of a healthy mammal, and which are not specifically products of tumor cells.

The term "statistically significant number of genes" in the context of this invention differs depending on the degree of change in gene expression observed. The degree of change in gene expression varies with the type of cancer and with the size or spread of the cancer or solid tumor. The degree of change also varies with the immune response of the individual and is subject to variation with each individual. For

example, in one embodiment of this invention, a large change, e.g., 2-3 fold increase or decrease in a small number of genes, e.g., in from 5 to 8 characteristic genes, is statistically significant. This is particularly true for cancers without solid tumors. In another embodiment, a smaller relative change in about 30 or more genes is statistically significant. This is particularly true for cancers with solid tumors. Still alternatively, if a single gene is profiled as up-regulated or expressed significantly in cells which normally do not express the gene, such up-regulation of a single gene may alone be statistically significant. Conversely, if a single gene is profiled as down-regulated or not expressed significantly in cells which normally do express the gene, such down-regulation of a single gene may alone be statistically significant. As an example, a single gene, which is expressed about the same in all members of a population of patients, is 4-fold down regulated in only 1% of individuals without cancer. Four such independently regulated genes in one individual, all 4 fold down-regulated, would occur by chance only one time in 100 million. Therefore those 4 genes are a statistically significant number of genes for that cancer. Alternatively, if normal variance is higher, e.g., one healthy person in 10 has the gene 4-fold down-regulated, then a larger panel of genes is required to detect variance for a particular cancer.

Thus, the methods of this invention contemplate examination of the expression profile of a "statistically significant number of genes" ranging from 1 to 100 genes in a single profile. In one embodiment, the gene profile is formed by a statistically significant number of at least 1 gene. In another embodiment, the gene profile is formed by a statistically significant number of at least 4 genes. In still another embodiment, the gene profile is formed by at least 10 genes. In still other embodiments, the gene profiles examined as part of these methods, particularly in cases in which the cancers are characterized by solid tumors, contain, as statistically significant numbers of genes, 20, 30, 40, 50, 60, 70, 80, or 90 genes in a panel.

The terms HA-01 through HA-06 refer to microarrays of known genes. These microarrays are publically available and sold by the Genomics facility of The Wistar Institute, Philadelphia, PA. The lists of the genes forming these microarrays and means for ordering the arrays are published on the internet at (<http://www.wistar.upenn.edu/researchfacilities/facilities/genomics/review.html>). However, one skilled in the art may readily reproduce such microarrays by use of the

sequences of the genes, all of which are publicly available from conventional sources, such as GenBank.

B. Gene Expression Profile and Use in Diagnostic Methods

According to the present invention, there is provided a method of diagnosing a cancer in a mammalian subject. Since the body is under continuous surveillance by the immune system for evidence of infection or aberrant cells (Dunn, G.P., *et al.*, 2002 *Nat Immunol* 3:991-998.), a sampling of immune cells from the peripheral blood, properly analyzed, can be used to diagnose any condition which is detected as abnormal, including cancer. Expression profiling from non-tumor cells in peripheral blood is useful as a diagnostic tool for cancer detection, because there are effects of cancer cell or tumor growth on gene expression of various classes of immune cells found in the peripheral blood, and the effects have sufficient specificity for cancer or tumor type to indicate, e.g., the localization of the tumor if it has not metastasized to multiple sites or the stage of cancer, if metastatic. Similarly, expression profiling using circulating cancer cells from peripheral blood is useful as a diagnostic tool for cancer detection, because there are effects of cancer cell or tumor growth directly expressed on the cancer cells or tumor cells themselves.

A method of developing a gene expression profile indicative of the presence or stage of a selected a disease, disorder or genetic pathology in a mammalian subject includes the following steps. A first array of expression levels of a plurality of genes obtained from a biological sample of one or more patients having the disease, disorder or genetic pathology in question is assembled by conventional means. Preferably, the sample contains immune cells or cancer cells. Expression of the genes is analyzed in comparison to expression of the same genes in a second array of genes obtained from the same source of biological tissue or fluid from one or more healthy controls or from one or more patients having a different disease, disorder or genetic pathology that the one in question.

Penalized discriminant analysis is applied to the first array by comparison to a second array of expression levels of a plurality of genes. PDA is an extension of Fisher's linear discriminant analysis, which allows analysis of problems in which the number of variables greatly exceeds the number of examples. So, PDA is well adapted to microarray analysis. PDA is described, e.g., in Hastie, T., *et al*, 1995 *Annals of*

Stats., 23:73-102. This analysis is coupling with recursive feature elimination.

Recursive feature elimination is applied to the first array to identify and eliminate the least informative up-regulated and down-regulated genes from the comparison. In every comparison or analysis, a number (preferably an equal number) of the least
5 informative up-regulated and down-regulated genes are eliminated from the profile, which is then analyzed. For example, genes in excess of 800 are reduced in increments of 100 to 800 genes. From 800 to 400, the decrement is 20 genes, and from 400 to 2, the decrement is 2 genes. Shrunk centroids are used to determine whether any known classes of the disease or disorder in question have a distinct expression profile.
10 Shrunk centroid analysis is a new univariate algorithm for multiclass classification recently described by Tibshirani, R., *et al.*, 2002 *Proc Natl Acad Sci USA* 99:6567-6572. The resulting class is compared separately to controls and samples from patients with other types of cancer in subsequent analyses using PDA. The addition of recursive feature elimination to PDA is preferably included in the program for PDA so
15 that this analysis is performed automatically.

These steps are optionally repeated until a gene expression profile for the disease in question containing a statistically significant number of genes that vary in expression from the expression thereof in the array of said healthy or disease control, is obtained. This gene expression profile is a characteristic of the selected disease, disorder or genetic pathology or a stage of said selected disease, disorder or genetic pathology. PDA with recursive feature analysis is a technique that to Applicants' knowledge has not previously been applied to the evaluation or diagnosis of disease.

It is anticipated that this process can work similarly to generate characteristic gene expression profiles for disorders including cancer, and any genetic pathology that is diagnosed by characteristic variances in gene expression.

In other embodiments of the methods of this invention, one can employ other
20 known techniques to develop the expression profile of certain genes normally expressed in immune cells or in cancer cells. Transcription profiling using cDNA microarrays collects information about the expression level of thousands of genes and is an extremely sensitive method for distinguishing between cell types or between different differentiation states or physiological states of the same cell type. See, e.g.,
25 Khan, J *et al.*, 2001 *Nat Med* 7:673-679; Golub *et al.*, cited above; Hamalainen *et al.*,

cited above. Another useful method for establishing an expression profile is the use of support vector machines analysis.

5 In one embodiment, this method involves examining a sample containing immune cells of the disease subjects to obtain a gene expression profile of a statistically significant number of non-tumor genes in the immune cells. Preferably, as described above, an embodiment of this method results in an expression profile involving the expression characteristics of at least four non-tumor genes. In other embodiments, an expression profile involves characteristics of more than 30 genes. Still other statistically significant numbers of genes of greater than 50 may form a profile as described above.

10 The number and identity of the statistically significant genes associated with a particular type or location of a tumor accurately and sensitively assign a new patient to a class (diseased or healthy). See, for example, the genes listed immediately below and in the following Tables 1 and 11-15, among others. Statistically significant variances in the expression profiles of the patient from those of the normal/diseased profiles correlate with a cancer type and/or location of a solid tumor.

15 Uses of the methods of this invention are described in detail in the examples below. These methods and results for an exemplary immune cell cancer, cutaneous T cell lymphoma, as well as for exemplary solid tumor cancers, such as lung cancers are summarized below. These gene expression profiles may then be employed in diagnosis, staging and therapy monitoring of specific individual patients.

20 Another embodiment of this invention includes a method of diagnosing or staging a disease, disorder or genetic pathology in a mammalian subject. The steps of such a diagnostic method include comparing the expression of a statistically significant number of genes obtained from a biological sample of the individual subject containing immune cells or cancer cells and to a gene expression profile characteristic of the selected disease, disorder or genetic pathology or a stage of the selected disease, disorder or genetic pathology and to a gene expression profile from a similar biological sample of a healthy subject. Variance in the expression of genes in the patient sample from those of the characteristic gene expression profiles is analyzed. Variance in expression of patients' genes compared to a normal control and similarly to the

characteristic gene expression profile correlates with the type and/or location of the disease, disorder or genetic pathology.

For example, a profile established for the patient sample in question is compared with characteristic immune cell gene expression profiles or profiles of gene expression from other tissue from a number of normal, healthy control subjects and from subjects with known diseases. The detection algorithm of the method employed
5 compares the profile of the new patient with that of the average healthy/diseased profiles previously established and returns a mathematical value or score reflecting which population the new patient most closely resembles.

Such characteristic gene expression profiles may desirably be included in diagnostic kits for the diseases or disorders in question.

10 ***I. Non-Solid Tumor Profiles, i.e., CTCL***

Expression profiles for diagnosis of cancers in which cancer cells are found in the peripheral blood can be generated by the methods of this invention. Thus, in another embodiment of this invention as supported in Examples 1-6 below, cDNA microarrays were used to study gene expression patterns in patients with a selected
15 cancer that is not characterized by solid tumors, i.e., Sezary Syndrome, the leukemic form of cutaneous T-cell lymphoma (CTCL). These cDNA microarrays identified markers useful for diagnosis and prognosis and provided new targets for therapy. Specifically, the method of this invention identified gene expression profiles in peripheral blood mononuclear cells that could diagnose patients with leukemic forms of
20 cutaneous T-cell lymphoma, primarily Sezary syndrome.

Gene expression profiles of peripheral blood mononuclear cells (PBMC) from patients with the high numbers of circulating Sezary cells were analyzed using cDNA arrays.

a. Selection of Significant Genes.

25 The analysis of gene expression in patients with high Sezary cell counts was compared to Th2 skewed PBMC control cells from healthy volunteers. Th2 skewed PBMC was used as the standard for comparison because of the overwhelming evidence of the Th2 nature of Sezary cells. In this way, the detection of differences, which were related to Th2 differentiation, rather than the development of CTCL, was minimized.
30 Patients were tested against 4500 unique genes. In comparing Th2 skewed controls to

patients, significant changes in gene expression are found for less than 10% of the genes on the arrays. A comparable number of changes are found (data not shown) when comparing normal PBMC to PBMC skewed to a Th1 or Th2 response, suggesting very few events are required to alter expression of so many genes. Nevertheless, the changes in expression observed account for many of the observed characteristics of the disease, provide markers for diagnosis, and prognosis and may also provide targets for therapy.

A univariate t-test was used as a primary screen to determine the number of genes that are differentially expressed between the high Sézary cell patients and Th2 skewed controls. Two thresholds of significance were used for the different analyses (Allison, D.B., *et al* 2002 *Computational Statistics and Data Analysis* 39:1-20). Because of patient variability, the most accurate class distinctions between patients and controls or early and late-stage disease must be based on expression levels of many genes. When expression data for patients with high blood tumor burden (Sezary cells > 60% of the lymphocytes) and healthy controls were compared by t-test, at $p < 0.01$, 385 genes were differentially expressed. The genes selected at the $p < 0.01$ threshold included few false positives, exhibited low variance among patients, and were likely to be the most useful for understanding the biology of CTCL and for designing single-gene diagnostic reagents.

Numerous genes with $p > .01$ that were informative as a group, even though their individual variability was high.

Using penalized discriminant analysis (PDA) (Hastie, T *et al*, 1995 *Annals of Statistics* 23:73-102; Raychaudhuri, S. 2001 *TIBS* 19:189-193), trained on patients with high Sezary cell counts, several small groups of genes were identified that were able to accurately classify patients with high tumor burden (60-99% of circulating lymphocytes) from normal controls with 100% accuracy.

When patients with lower tumor burden (5-62% of circulating lymphocytes) were tested according to this method, a panel of 8 genes was identified that can correctly distinguish Sezary syndrome in patients with as few as 5% circulating tumor cells from normal controls with 100% accuracy. These results suggest that even in early disease, Sezary cells produce chemokines and cytokines that induce an expression profile in the peripheral blood distinctive to

Sezary syndrome. The ability to identify patients with as few as 5% circulating Sezary cells using PDA suggests that the malignant cells, as a function of the cytokines and chemokines they release, induce a pattern of gene expression in the peripheral blood that is distinctive to CTCL.

5 b. *Expression of Genes Associated with Th2 Differentiation.*

The array studies confirmed and extended evidence of the skin homing and Th2 nature of Sezary cells. Highly overexpressed genes required for Th2 differentiation included Th2 specific transcription factors Gata-3, which also suppresses Th1 development (Grogan, J.L., *et al.*, 2001 *Immunity* 14:205-215; Rao, A., and O. Avni. 2000 *Br Med Bull* 56:969-984), and JunB required for Th2 specific IL-4 transcription (Li, B., *et al.*, 1999 *Embo J* 18:420-432). Amplification and overexpression of JunB was recently described in a subset of CTCL patients (Mao, X., *et al.* 2003 *Blood* 101:1513-1519).

Other highly overexpressed genes included genes that are important for tissue specific homing characteristic of Th2 cells, such as selectin-L ligand, preferentially found on CD4⁺ cells expressing Th2 cytokines (Kannagi, R. 2000 *Seikagaku* 72:1399-1415); selectin-P ligand, which forms the skin homing cutaneous lymphocytic antigen (CLA-1) when modified by alpha-fucosyl transferase (Pober, J.S., *et al.* 2001 *Ann N Y Acad Sci* 941:12-25); and integrin β -1 (Jaspars, L.H., *et al.* 1996 *J Pathol* 178:385-392; Clissi, B., *et al.*, 2000 *J Immunol* 164:3292-3300), another marker for skin-homing T-cells. Still other highly overexpressed genes included proteoglycan 2, the RhoB oncogene, and dual-specificity phosphatase-1.

Highly underexpressed genes included CD26, Stat-4 and the Interleukin 1 receptors.

25 c. *Genes That Affect Apoptosis.*

There has been much speculation that CTCL cells are defective in their apoptotic pathways. However, observations at the message level from the array studies are not, in all cases, consistent with this hypothesis. The antiapoptotic gene Bcl2 was underexpressed in the samples. Additionally, although Fas ligand message levels were decreased, T-cell associated Fas message levels were essentially unchanged. Several other patterns of gene expression that contribute to a defect in the apoptotic pathways were found.

The overexpression of the proinflammatory cytokine IL-1 β , a primary activator of T-cell death pathways (Luft, T., *et al*, 2002 *J Immunol* 168:713-722), and Caspase 1 required for IL-1 β activation, was unexpected in light of the primarily anti-inflammatory phenotype exhibited by patients. However, IL-1 β overexpression is offset by the significant underexpression of both IL-1 receptors (IL-1Rs) in patients, suggesting this important apoptotic pathway is inactive in CTCL cells. The significance of the underexpression of the IL-1Rs to CTCL is supported by PDA studies that identify the reduction in IL-1R expression as second only to that of STAT4 in classifying patients and controls.

The chemokine receptor CX3CR1 is normally expressed on Th1 but not on Th2 T-cells (Fratice, P., M. *et al*, 2001 *J. Clin. Invest.* 107:1173-1181), yet it was overexpressed by more than 4-fold in patients. In the CNS, CX3CR1 on microglia is suggested to prevent Fas mediated cell death in response to stress (Boehme, S.A., *et al*, 2000 *J Immunol* 165:397-403). If CX3CR1 has a similar function in Sezary cells, this could also contribute to the proposed apoptotic defect in these cells. ICAM 2, also overexpressed, has been shown to suppress TNF- α and Fas-mediated apoptosis through its activation of the PI3K/AKT pathway (Perez, O.D., *et al*, 2002 *Immunity* 16:51-65). AKT overexpression has been associated with a variety of different cancers. The combined up-regulation of genes known to interfere with apoptosis, such as CX3CR1 and ICAM2, and down-regulation of the IL-1R's contributes to the observed resistance to apoptosis in Sezary cells.

d. Genes not Normally Expressed in Th2 T-Cells.

There are presently no CTCL specific markers. Identification of genes expressed in the malignant T-cells, which are not normally expressed in that cell type can be very useful for diagnosis and perhaps act as targets for intervention. The plastin gene family has three known members that function as actin bundling proteins and have tissue restricted expression patterns (Namba, Y., *et al*, 1992 *J Biochem (Tokyo)* 112:503-507), i.e., Plastins 1, 2 and 3, also known as Plastins L, I and T, respectively that are highly conserved in sequence. Tissue plastin (PLS3) is expressed in a variety of tissues but not in normal lymphoid cells that express lymphoid cell plastin (LCP1) instead.

In the present invention, the cDNA microarrays detected message for plastin-T, not normally expressed in lymphoid tissue, only in patient samples. LCP1 was abundantly expressed in both patients and controls, but inappropriate PLS3 expression is restricted to the CTCL samples. PLS3 expression was detected in 35 of the 45 patient samples surveyed by arrays. Both lymphoid and tissue plastins were co-expressed in all cases. Transfection studies have suggested that these highly related proteins have differences in localization patterns and in their interactions with cytoskeletal accessory proteins and therefore may have somewhat different functions (Arpin, M., *et al.* 1994 *J Cell Biol* 127:1995-2008).

The inappropriate expression of a non-lymphoid marker, such as PLS3, and a non-Th2 marker, such as CX3CR1, in the malignant cells are thus useful as robust markers for diagnosis. Thus the present invention further presents these genes as new single gene markers for diagnosis of CTCL. Ligands that bind specifically to tissue plastin (PLS3) are presented below as new diagnostic reagents for diagnosis of CTCL according to this invention. These ligands can identify the presence of PLS3, even in the company of other plastin forms.

e. Genes That Have High Predictive Power to Classify Patients and Controls.

The loss of STAT4 expression in CD4⁺ Sezary cells was noticed in a small group of patients (Showe, L.C., *et al.*, 1999 *J Immunol* 163:4073-4079), and further observed in the 45 patient samples analyzed in the examples below. The loss of expression of Stat-4, which is required for Th1 T-cell differentiation (Frucht, D.M., *et al.* 2000 *J Immunol* 164:4659-4664; Fukao, T. *et al.*, 2001 *J Immunol* 166:4446-4455), is one of the most significant characteristics of CTCL patient samples. STAT4 is one of two genes that can be used in PDA to classify high Sezary cell patients from controls by themselves and one of eight genes that classify patients with low percentages of circulating Sezary cells, suggesting that the loss of STAT4 is an early event in the development of CTCL.

The small GTPase, RhoB is another of the top classifiers identified in the PDA studies. Like PLS3, RhoB interacts with the actin cytoskeleton. As a GTP binding protein RhoB has the capacity to modulate downstream events, and its activity is dependent on post-translational modifications that can be catalyzed by either farnesyl

transferases or geranyltransferases. Farnesyl transferase inhibitors have been under intense scrutiny for their potential in treating cancers that harbor Ras mutations.

Although there are some observations that contradict the model (Namba, Y. *et al.*, 1992 *J Biochem (Tokyo)* 112:503-507), there is a large body of evidence that supports the hypothesis that the efficacy of these inhibitors in treating cancers is due to their effects on RhoB (Cruil, M., *et al.* 2001 *Anticancer Drugs* 12:163-184; Prendergast, G.C. 2001 *Nature Rev Cancer* 1:162-168; Sebt, S.M., and A.D. Hamilton. 2000. *Expert Opin Investig Drugs* 9:2767-2782).

Although the high Sezary cell patients and controls were classified with as few as two genes, STAT4 and RhoB, biomarkers that could identify patients with low tumor burdens that are more difficult to recognize clinically were also identified. When the classification gene set was reduced to the twenty top genes, all controls and all but one patient were properly classified. On reexamination, the misclassified patient had skin findings typical of Kimura's disease (Lichter, H., *et al.*, 1998 *Harefuah* 134:760-762, 832) but blood findings in keeping with leukemic phase CTCL including a high CD4⁺/CD8⁺ ratio, eosinophilia, and a circulating T-cell clone identified by a chromosomal abnormality. Despite the many similarities to SzS, this Kimura's patient was properly identified by PDA. Expression patterns of Stat-4 and RhoB alone could be used to correctly classify 26 of the 29 CTCL patients and all but one untreated control, but there are many sets of ten genes that are as good as or better classifiers than these two genes.

f. Classification of Short Term Survivors.

Patients who are ST survivors, and are usually resistant to additional therapy, have a detectably different gene expression pattern from patients classified as MT and LT survivors, independent of their tumor burden. PDA was used to identify expression patterns of 10 genes, which distinguish patients with short survival times (i.e., who will succumb within six months of sampling), regardless of the blood tumor burden when they were sampled. Thus, diagnosis of an advanced stage of Sezary syndrome is possible by monitoring expression patterns of these 10 genes by microarray analysis of tumor or blood samples in a clinical setting.

The finding of a "terminal signature" in these patients has a number of implications. Perhaps the most obvious and important is that an accumulation of

a high percentage of Sezary cells is not an optimal index of the severity of disease. Since CTCL patients may die from a number of different causes, it is striking that a characteristic gene expression pattern can be detected in their peripheral immune cells when death is imminent. This pattern is useful in identifying patients who might benefit from more aggressive therapies that would otherwise not be recommended until later times.

In another specific embodiment of this invention disclosed in the examples below, a simple and reliable method for diagnosis of SzS is disclosed using quantitative real time PCR (qPCR) measurements and linear discriminant analysis (LDA). For simplicity, this procedure is referred to as DAPD (Discriminant analysis of quantitative PCR (qPCR) data). Because LDA assigns a predictive score to each classified sample, a confidence level is associated with each result making this approach robust and simple to apply. Using expression levels of STAT4, Cd1d, GATA3, TRAIL and PLS3 in purified PBMC, CTCL patients are diagnosed with 95% accuracy, including those with as few as 5% circulating malignant cells. Detection of PLS3, normally not expressed in lymphoid cells, is by itself diagnostic for 70% of the patients tested.

This invention thus provides a composition and method of diagnosis that is effective for identifying early disease. Such a method/assay must be able to accurately diagnose patients with very few tumor cells as well as those with high tumor burden. In developing the diagnostic method, 4 different criteria were met. First, the material to be assayed is easily accessible. Second, the technology is robust and can be easily applied at different locations. Third, the false positive and false negative calls are low; and fourth, the classification gives a measure of the accuracy of diagnosis.

Successful diagnosis based on the expression of just a few genes is made possible in this invention by identifying the best discriminant genes from 5800 genes analyzed in microarray experiments, and by the showing that the results are replicable using two different methodologies, i.e., microarray and qPCR, with the same accuracy (FIGS. 1A-1F). The present invention's diagnostic method is a platform independent, discriminant method. Instead of using the calculated gene expression values, which can be different for different methods and might vary from one clinical setting to another, the relative ranks of gene expression are used in this method. By using the ranks of gene expression, the analysis is remarkably robust. It is also method independent, in the

sense that genes selected by microarrays of amplified RNA can be used to diagnose by PCR using total RNA. The discriminant function itself is transferable from one method to another, if a calibration standard is employed.

As shown in the examples below, for the selected genes, LDA trained on
5 datasets acquired either by arrays or PCR and using either aRNA or total RNA produce virtually identical classification of the test sets. As a result, analysis of patient samples does not require that the "training set" be performed on the same platform, although a single sample should be carried from one platform to the next to standardize the gene ranks. LDA using gene ranks was 99% accurate on the data of Gordon *et al*, cited
10 above with 4 genes, and 100% accurate with 5 genes. The ratio-based method of Gordon *et al* was 95% and 99% percent accurate respectively on the same data.

An additional positive characteristic of the DAPD classification method of the present invention is that each sample receives a quantitative score that is a measure of its quality of classification by the genes being tested. Although only five genes were
15 used in the examples, that number is increased to further characterize patients that appear to be close to the cut-off. The set of five genes used in the examples for diagnosis of CTCL is not the only possible classifier. The array studies identified several small sets of genes that were equally good at classifying patients and control samples, and are equally good at diagnosis by DAPD. It is anticipated that because of
20 the known relationship between MF and SzS, genes identified in these examples may also be useful in the diagnosis of MF, the most frequently misdiagnosed form of CTCL.

Thus, use of the methods of this invention permit early diagnosis of CTCL and staging of terminal CTCL by monitoring expression patterns of a small number of genes by microarray analysis of tumor or blood samples in a clinical setting. These
25 methods and the results obtained thereby are described in detail in the following examples.

The following Table 1 provides an additional list of genes significant for use in the methods of this invention and for which the PDA with recursive feature elimination technique can be applied, as described herein. The gene names and symbols are
30 indicated. All of these genes are upregulated. Table 1, Column A lists the genes in order of significance for diagnosis of CTCL, i.e., the best classifiers of CTCL by PDA according to this invention. Column A lists the genes in ratio of gene expression in

purified CTCL tumor cells to expression in the corresponding normal cells (i.e. CD4 T cells). The listings from 1 to 100 reflect relative levels of significance.

Table 1, Column B provides the significant genes showing the best correlation with per cent SzS cells, i.e., genes the expression of which best reflects tumor burden.

5 The number assigned to each gene reflects relative levels of significance in this column with 1 as most important. When comparing unpurified patient PBMC to unpurified normal PBMC, the ratio of the expression levels of these genes most highly correlates with the percentage of tumor cells in the patient. That is, a patient with 90% circulating tumor cells has a very high ratio compared to a patient with only 5 or 10%. This is
10 likely true because more tumor cells affect all the PBMC to a greater degree than few tumor cells, but it is possible that these genes are mainly in the tumor cells themselves.

Table 1, Column C lists those genes most useful for detecting disease in unpurified PBMC, i.e., genes which are most informative at classification when comparing PBMC from patients to PBMC from normals. This reflects differences
15 which characterize the disease state and not necessarily changes specific to the tumor cells. The number assigned to each gene reflects relative levels of significance in this column with 1 as most important.

TABLE 1

GENE NAME	SYMBOL	A	B	C
plastin 3 (T isoform)	PLS3	1	36	4
tumor necrosis factor (ligand) superfamily, member 7	TNFSF7	2	35	2
cysteine dioxygenase, type I	CDO1	3	18	34
liver-specific bHLH-Zip transcription factor	LISCH7	4	39	70
tumor necrosis factor (ligand) superfamily, member 11	TNFSF11	5	48	3
ESTs, Highly similar to A35049 ankyrin 1, erythrocyte splice form 2 - human [H.sapiens]	N/A	6	70	13
calcium channel, voltage-dependent, alpha 2/delta subunit 1	CACNA2D1	7	27	36
Proteglycan 4	PGR4	8	1	54
fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome)	FGFR1	9	14	29
PAS domain containing serine/threonine kinase	PASK	10	8	35
chromosome 18 open reading frame 1	C18orf1	11	92	32
tumor necrosis factor (ligand) superfamily, member 9	TNFSF9	12	38	5
Homo sapiens cDNA FLJ32507 fis, clone SMINT1000048, moderately similar to Mus musculus GTPase Rab37 mRNA, mRNA sequence	N/A	13	67	12

cadherin 1, type 1, E-cadherin (epithelial)	CDH1	14	49	31
cell division cycle 25B	CDC25B	15	16	24
Homo sapiens cDNA FLJ36496 fis, clone THYMU2018819, mRNA sequence	N/A	16	64	11
tumor suppressing subtransferable candidate 4	TSSC4	17	74	30
GS3955 protein	GS3955	18	11	33
transducer of ERBB2, 1	TOB1	19	69	1
GATA binding protein 3	GATA3	20	2	25
EST, Highly similar to JC2398 PMS3 homolog mismatch repair protein - human [H.sapiens]	N/A	21	54	9
pleckstrin homology, Sec7 and coiled/coil domains 1(cytohesin 1)	PSCD1	22	60	80
ESTs, Highly similar to IgG Fc binding protein [Homo sapiens] [H.sapiens]	N/A	23	59	10
5-hydroxytryptamine (serotonin) receptor 2B	HTR2B	24	45	38
Homo sapiens cDNA FLJ32847 fis, clone TESTI2003376, mRNA sequence	N/A	25	46	8
TEA domain family member 4	TEAD4	26	61	81
gamma-aminobutyric acid (GABA) A receptor, alpha 1	GABRA1	27	15	22
annexin A6	ANXA6	28	71	28
nucleolar protein family A, member 1 (H/ACA small nucleolar RNPs)	NOLA1	29	79	87
serum-inducible kinase	SNK	30	41	71
tumor necrosis factor receptor superfamily, member 25	TNFRSF25	31	5	53
src family associated phosphoprotein 1	SCAP1	32	28	66
brain-specific protein p25 alpha	p25	33	31	67
chemokine (C-C motif) receptor 7	CCR7	34	58	79
kangai 1 (suppression of tumorigenicity 6, prostate; CD82 antigen (R2 leukocyte antigen, antigen detected by monoclonal and antibody IA4))	KAI1	35	42	52
asparagine synthetase	ASNS	36	13	48
ESTs, Moderately similar to 2203412A polycystin [Homo sapiens] [H.sapiens]	N/A	37	93	20
keratin 1 (epidermolytic hyperkeratosis)	KRT1	38	68	44
lymphocyte-specific protein tyrosine kinase	LCK	39	76	84
ESTs, Highly similar to serine/threonine kinase 14 alpha [Homo sapiens] [H.sapiens]	N/A	40	84	17
aquaporin 3	AQP3	41	22	63
Homo sapiens full length insert cDNA clone YI61E07, mRNA sequence	N/A	42	10	7
EST	N/A	43	80	15
pim-2 oncogene	PIM2	44	19	60
similar to RIKEN cDNA 1110002C08 gene	MGC9564	45	65	41
ESTs, Highly similar to cadherin EGF LAG seven-pass G-type receptor 2; EGF-like-domain, multiple 2; epidermal growth factor-like 2; multiple epidermal growth factor-like domains 3; cadherin, EGF LAG seven-pass G-type receptor 2, flamingo	N/A	46	82	16

(Drosophila) homo				
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4	KCNN4	47	63	43
mevalonate (diphospho) decarboxylase	MVD	48	51	75
uracil-DNA glycosylase	UNG	49	20	61
bridging integrator 1	BIN1	50	98	95
endothelial differentiation, sphingolipid G-protein-coupled receptor, 1	EDG1	51	12	58
transcription factor 7 (T-cell specific, HMG-box)	TCF7	52	47	73
paraneoplastic antigen MA1	PNMA1	53	43	72
hypothetical protein FLJ20551	FLJ20551	54	52	76
EST	N/A	55	88	19
		56	9	57
hypothetical gene BC008967	BC008967			
hypothetical protein MGC14439	MGC1443	57	94	92
fatty-acid-Coenzyme A ligase, long-chain 6	FACL6	58	29	23
interleukin 11 receptor, alpha	IL11RA	59	21	62
collagen, type VI, alpha 3	COL6A3	60	83	47
T cell receptor beta locus	TRB@	61	55	77
Homo sapiens full length insert cDNA clone YI61E07, mRNA sequence	N/A	62	4	--
FtsJ homolog 1 (E. coli)	FTSJ1	63	6	56
coproporphyrinogen oxidase (coproporphyrin, harderoporphyrin)	CPO	64	96	27
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)	CXCL1	65	56	37
guanylate cyclase activator 2B (uroguanylin)	GUCA2B	66	95	93
SH2-B homolog	SH2B	67	75	83
TNF-induced protein	GG2-1	68	78	86
ligase I, DNA, ATP-dependent	LIG1	69	62	82
cytochrome P450, subfamily XXIV (vitamin D 24-hydroxylase)	CYP24	70	66	26
CD28 antigen (Tp44)	CD28	71	73	51
diacylglycerol kinase, alpha 80kDa	DGKA	72	30	46
5',3'-nucleotidase, cytosolic	NT5C	73	90	90
ankyrin 3, node of Ranvier (ankyrin G)	ANK3	74	87	89
cofilin 2 (muscle)	CFL2	75	97	94
peroxisomal biogenesis factor 12	PEX12	76	86	88
CDC14 cell division cycle 14 homolog A (S. cerevisiae)	CDC14A	77	24	65
HSPC041 protein	LOC51125	78	37	69
Down syndrome critical region gene 1-like 2	DSCR1L2	79	33	49
death associated protein 3	DAP3	80	103	98
tumor protein p53 binding protein, 1	TP53BP1	81	53	40
CD4 antigen (p55)	CD4	82	32	68
translocase of outer mitochondrial membrane 70 homolog A (yeast)	TOMM70A	83	77	85
IL2-inducible T-cell kinase	ITK	84	17	59
EST	N/A	85	101	21
acetyl-Coenzyme A acetyltransferase 2 (acetoacetyl Coenzyme A thiolase)	ACAT2	86	3	55

EphA1	EPHA1	87	40	74
cysteine-rich protein 2	CRIP2	88	89	45
profilin 2	PFN2	89	100	97
RNA cyclase homolog	RNAC	90	34	39
recoverin	RCV1	91	99	96
ESTs, Highly similar to C5HU complement C5 precursor - human [H.sapiens]	N/A	92	85	18
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 3	MLLT3	93	40	50
ectodermal-neural cortex (with BTB-like domain)	ENC1	94	57	78
azurocidin 1 (cationic antimicrobial protein 37)	AZU1	95	91	91
hypothetical protein MGC17330	MGC17330	96	7	42
CD5 antigen (p56-62)	CD5	97	23	64
ESTs, Moderately similar to PIGC_HUMAN Phosphatidylinositol-glycan biosynthesis, class C protein (PIG-C) [H.sapiens]	N/A	98	72	14
tumor necrosis factor receptor superfamily, member 7	TNFRSF7	--	25	--
fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome)	FGFR1	--	26	--
fatty-acid-Coenzyme A ligase, long-chain 6	FACL6	--	44	--
ESTs, Highly similar to cadherin EGF LAG seven-pass G-type receptor 2; EGF-like-domain, multiple 2; epidermal growth factor-like 2; multiple epidermal growth factor-like domains 3; cadherin, EGF LAG seven-pass G-type receptor 2, flamingo (Drosophila) homo	N/A	--	81	--
tumor necrosis factor receptor superfamily, member 7	TNFRSF7	--	--	6

Application of the methods of this invention to such lists of genes can produce characteristic gene expression profiles useful as diagnostic signatures indicative of CTCL. Comparable diagnostic signatures are detectable in the immune cells of patients with other types of cancers, e.g., those with solid tumors, and other types of diseases. For example, one gene expression profile indicative of the presence or stage of CTCL contains expression levels of a statistically significant number of genes selected from the genes encoding PLS3, STAT4, TRAIL, CD26, RhoB, GATA3, TNFRSF5, SCYA2, PF4, CSPG2, S100A12, KLF4, ARHB, KAL1, JUNB, DUSP1, ITGB1, TOB1, GS3955, IL11RA, Clorf29, MNDA, CD1D, CX3CR1, DTR, RPA3, MADH7, CD79A, PLAUI, SEC61G, and SCYA4.

2. Solid Tumor Profiles

In one embodiment, the genes in the characteristic expression profile for a cancer characterized by a solid tumor, which demonstrate a variance from normal controls in a patient with a solid tumor, are genes associated with cell growth. Exemplary genes associated with cell growth include, without limitation, PTMA, HNRPA1, RPL41, SERPINB6, TACC1, CX3CR1, and HNRPA2B1. In another embodiment, the genes in the expression profile, which demonstrate a variance from normal controls in a cancer patient, are genes associated with actin remodeling. Such actin remodeling genes include, without limitation, ACTR1A, ARPC3, WASF2, SMARCA5, ACTB ARPC4 and MYO1F. In another embodiment, the genes in the expression profile, which demonstrate a variance from normal controls in a cancer patient, are genes associated with energy production. Some exemplary energy production genes include, without limitation, LDHA, LDHB, and ATP5G3. In yet another embodiment, the genes in the expression profile, which demonstrate a variance from normal controls in a cancer patient, are genes associated with mitosis. Such mitosis-associated genes include, without limitation, NIMA, CCNF, CDC25A and CDC25B. In yet another embodiment, the genes in the expression profile, which demonstrate a variance from normal controls in a cancer patient, are genes associated with natural killer cells (NK) and genes associated with cytotoxic T cells (CTL). Such NK and CTL genes include without limitation, FCGR3A, GNLY, PRF1, CD8A, CD2, IS2RG, GZMK, ITGAM, PFN1, TIA1, GZMB, and IL2RB.

In one embodiment of the methods of this invention, Examples 7-9 demonstrate gene expression analysis in peripheral blood lymphocytes from patients at early and late stages of solid tumors and normal controls. Both T-cell lymphoma and 6 different types of advanced solid tumors create expression profiles in peripheral blood mononuclear cells which are easily distinguished from the corresponding profiles obtained from healthy volunteers. As indicated in the example below, the samples from patients with solid tumors can be easily distinguished from controls by hierarchical clustering (see, e.g., Eisen *et al* 1998 *Proc. Natl. Acad. Sci. USA*, 95:14963-14868; Sorlie, T., *et al.*, 2001 *Proc Natl Acad Sci U S A*, 98:10869-10874) or supervised procedures including shrunken centroids (Tibshirani, R., *et al.*, 2002 *Proc Natl Acad Sci U S A* 99:6567-6572) or penalized discriminant analysis (PDA). These references are incorporated by reference for teachings concerning these techniques.

An example of expression profiles generated from samples from NSCLC patients, patients with a variety of cancers, including adrenal, ovarian, pancreatic mesothelioma, and sarcoma, and controls using hierarchical clustering is shown in FIG. 13. Expression profiles were established using the following panel of genes: cathepsin C, TIA1 cytotoxic granule-associated RNA binding protein, interleukin 2 receptor β , Fc fragment of IgG, low affinity IIIa, receptor for CD16, granzyme B, granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1, CD2 antigen p50, sheep red blood cell receptor, CD8 antigen, alpha polypeptide p32, integrin, alpha M complement component receptor 3 α (also known as CD11b), perforin, granzyme K serine protease, granzyme 3; tryptase II, profilin 1, interleukin 2 receptor, gamma severe combined immunodeficiency, and granulysin. As with all the treeviews, the black squares indicate up-regulated genes in the sample; the white squares indicate down-regulated genes; and the gradations of gray squares indicate genes with expressions of relative intermediate over- or under-expression depending upon their closeness to the black or white sides of the color scale.

In spite of the consistency of the cancer group, it has a substantially greater variance than the control group. Part of this variance stems from a variable degree of progressive failure of the immune response in cancer patients. Disease progression is estimated by projecting each sample on the AverageControl-AverageCancer vector, by the shrunken distance to control centroid, and by crossvalidation with PDA. To identify the most significant genes, either the median distance from the control centroid, or discriminant loadings obtained from PDA performed on Control-Cancer groups after the outliers have been removed is employed as the method. Two main groups were identified as having genes changed the most with disease progression. The highest scores obtained with both methods described above identified the first group, which contains genes associated with cell growth, actin remodeling, energy production, and mitosis. The second group was identified by selecting genes associated with NK cells and cytotoxic T-cells, and demonstrating that all of these genes are significantly downregulated. See FIG. 15.

For example, a characteristic gene expression profile indicative of the presence or stage of a solid tumor cancer comprising expression levels of a statistically significant number of genes selected from the genes encoding PTMA, HNRPA1,

RPL41, SERPINB6, TACC1, CX3CR1, and HNRPA2B1, ACTR1A, ARPC3, WASF2, SMARCA5, ACTB ARPC4, MYO1F, LDHA, LDHB, ATP5G3, NIMA, CCNF, CDC25A, CDC25B, FCGR3A, GNLY, PRF1, CD8A, CD2, IS2RG, GZMK, ITGAM, PFN1, TIA1, GZMB, and IL2RB.

5 **C. *Monitoring Method***

Another aspect of the present invention involves identifying or monitoring the effects of a therapeutic agent or regimen on a patient having a cancer. According to this method, a selected therapeutic agent or treatment regimen is administered to the patient. Periodically during and/or after administration of the agent or during and/or
10 after completion of the therapeutic regimen, a sample containing immune cells and/or cancer cells of the subject is examined for expression of a statistically significant number of non-tumor or tumor genes in the cells. One embodiment of this method employs an expression profile to diagnose a solid tumor cancer involving the expression characteristics of at least one non-tumor gene. Preferably, as described
15 above, an embodiment of this method employs an expression profile involving the expression characteristics of at least four non-tumor genes. Preferably, as described above, an embodiment of this method employs an expression profile involving the expression characteristics of at least eight non-tumor genes. In other embodiments, an expression profile involves characteristics of more than 10 genes or more than 30 or
20 more than 50 non-tumor genes, such as those listed specifically above and in the examples for solid tumor cancers. Still other statistically significant numbers of genes may form a profile as described above. The profile is obtained using the techniques as described above.

In other embodiments in which the cancer to be diagnosed is not characterized
25 by solid tumors, such as CTCL, an expression profile involves the expression characteristics of at least one gene that is the product of the cancer. Preferably, as described above, an embodiment of this method employs an expression profile involving the expression characteristics of at least four such genes. Preferably, as described above, an embodiment of this method employs an expression profile
30 involving the expression characteristics of at least eight such genes. In other embodiments, an expression profile involves characteristics between 10 to about 20 such genes or about 40 such genes, such as those listed specifically above and in the

examples for CTCL. Still other statistically significant numbers of genes may form a profile as described above. The profile is obtained using the techniques as described above.

5 Thereafter, this patient's current profile is compared to the same profile obtained from the patient prior to administration or treatment and to the characteristic disease profile. Optionally this current profile is also compared to a control profile, or average of a number of profiles, from one or a population of healthy subjects. A statistically significant variance in expression of the genes in the current profile from the prior profile or from the characteristic profile or that of normal controls indicates
10 the response of the patient to the therapy.

 Thus, this method is adapted to determine preferred therapies for individual patients, because different patients respond differently to the variety of existing therapies for cancer treatment. Application of this method enables the selection of the therapy for which the patient is most responsive. In fact, the invention contemplates
15 the establishment of multiple expression profiles for various cancers based on the collection of profiles of multiple cancer patients. The development of average profiles for certain cancers, as well as average profiles of patients responsive to selected therapies for selected cancers enables the use of a modified method of determining a patient's likely response to a selected therapy.

20 For example, the patient's own expression profile is obtained before any therapy is applied. The patient's profile is compared with the profiles of other populations of cancer patients, who were responsive to different types of therapies ("therapeutic profiles"). The therapeutic profile, which the patient's profile most closely matches, is used to predict the patient's response to that same therapy. Thus, this modified method
25 does not require that the patient be treated before the profile is obtained.

 Still other variations on these diagnostic methods are likely.

D. Screening Methods

 In yet another aspect, the present invention provides a screening method for identifying a cancer therapeutic agent or regimen useful for the treatment of a cancer.
30 This method can be employed to determine the appropriate selection from among many pharmaceutical reagents or therapies for the treatment of individual cancers or groups of cancers. According to this method, a selected therapeutic agent or treatment regimen

is administered to test a mammalian subject having a cancer. The test subject is desirably a research animal, e.g., a laboratory mouse or other. Periodically during and after administration of said agent or regimen, a sample containing immune cells of the test subject is examined and an expression profile of a statistically significant number of non-tumor genes is generated. The genes in the test profile are compared to the genes in a characteristic gene expression profile for a cancer. The characteristic profile is obtained and compared using the methods described above. Thereafter, this test subject gene profile is compared to the same profile obtained from the subject prior to the start of the therapy. Optionally the current subject profile can be compared to an average control profile from a population of healthy subjects. A variance in expression of the statistically significant genes is reviewed among the current profile, characteristic profile, healthy profile, and the prior profiles. If a variance in the current test profile is closer to the profiles of the normal control than to the disease profile, such results indicate that the therapeutic agent or regimen is a desirable cancer therapeutic for the particular cancer in question.

E. New Diagnostic Methods and Reagents for CTCL

The inventors surprisingly discovered that human tissue plasmin protein or PLS3 was uniquely expressed in the malignant T-cells of CTCL patients. As supported by the following examples, PLS3 is expressed only in patients and never in control PBMC, as expression of this gene is normally not found in lymphoid cells. This makes PLS3 an extremely sensitive marker for CTCL. Its presence is diagnostic for CTCL in 70 % of the patients tested. PLS3 is a 627 amino acid sequence SEQ ID NO: 1. See the NCBI database Accession No. P13797.

Thus, as one aspect of the invention, a novel diagnostic method for diagnosing CTCL involves detecting the presence of PLS3 in lymphoid cells of a suspected CTCL patient. Useful in such a method are ligands to PLS3, such as the ligands described below. An assay for detection of PLS3 may be employed to monitor the status of a CTCL patient undergoing therapy. The selection of particular assay steps for detection of PLS3 as a peptide or for detection of a nucleic acid sequence encoding PLS3 may be readily selected from among known assay formats by one of skill in the art. Such known assay formats, include, without limitation, e.g., ELISA, Western blotting, FACS analysis for protein or polymerase chain reaction, quantitative real-time PCR (qRT-

PCR) for nucleic acids, and immunofluorescence and confocal microscopy, among others. Such selection of assay steps is routine and does not limit the present invention.

For example, a method for diagnosing CTCL can involve detecting and identifying the level of expression of PLS3 in a patient by assaying a peripheral blood or whole blood sample with a labeled ligand capable of binding PLS3 or nucleic acid sequences encoding PLS3. The method includes the steps of incubating the subject's peripheral blood with plates or beads on which are bound one or more ligands to PLS3, washing away unbound biological materials, and detecting or measuring any PLS3 peptide or nucleic acid molecules expressing PLS3 remaining in the washed sample. Depending on the type of label employed, the signal produced by the label may be evoked by further adding a substrate which reacts with the enzyme, e.g., producing a color change or by irradiating the sample with an excitation wavelength suitable to detect a fluorochrome, among other methods. Other conventional labels may also be incorporated into this assay design.

The use of such ligands that bind the above-described epitope of PLS3 and the methods described herein provide a novel method of diagnosing most cases of CTCL.

Such ligands may be readily selected from among various antibodies to PLS3, antisense sequences or ribozyme sequences capable of hybridizing specifically to an amino acid or nucleic acid sequence encoding the designated epitope of PLS3. Similarly such ligands include those compositions that hybridize to naturally occurring variants of the polypeptide or nucleic acid sequences encoding the above-defined epitope.

In addition to known ligands to PLS3, the invention also discloses as another aspect of this invention a novel ligand which specifically binds to a PLS3 epitope sequence located within a peptide or polypeptide of the formula Ser-Lys-Asp-Glu-Leu-Asp-Glu-Leu-Lys-Glu-Ala-Phe-Ala-Lys (amino acids 7-20 of SEQ ID NO:1) or which specifically binds to a nucleic acid sequence encoding the above-defined peptide or polypeptide or other sequences specific to PLS3.

Another novel ligand is one that specifically binds to a PLS3 epitope sequence located within a peptide or polypeptide of the formula Arg-Glu-Ile-Ile-Gln-Lys-Leu-Met-Leu-Asp-Gly-Asp-Arg-Asn-Lys-Asp (amino acids 51-66 of SEQ ID NO:1) or

which specifically binds to a nucleic acid sequence encoding the above-defined peptide or polypeptide or other sequences specific to PLS3.

The term "antibody" as used herein is intended to encompass an isolated polyclonal, or monoclonal, synthetic or recombinant antibody of classes IgG, IgM, IgA, IgD and IgE. Antibody fragments are also useful, including without limitation, a Fab fragment, a Fab' fragment, a F(ab')₂ fragment or an Fc antibody fragment of one or more of the above intact antibodies. Similarly a single chain Fv antibody fragment or a recombinant construct comprising a complementarity determining region of an antibody may be employed as the antibodies useful in these methods. Further, a synthetic antibody or chimeric antibody or humanized antibody construct which shares sufficient CDRs to retain functionally equivalent binding characteristics of an antibody that binds a desired cell surface antigen may also be employed as the antibody of choice.

In one embodiment, an isolated antibody directed which binds PLS3 is a polyclonal antibody. Such antibodies are typically produced by immunizing a mammal, preferably a primate, with the above-defined peptide/polypeptide, optionally bound to a carrier. Such antibodies may be produced in laboratory animals, preferably primates, in transgenic animals, including so-called "humanized" transgenic animals. However, a desirable host for raising polyclonal antibodies to a composition of this invention includes humans. The titer of such polyclonal antibodies raised in the mammal exposed to the PLS3 epitope of this invention can be monitored by standard techniques, such as with an enzyme-linked immunosorbent assay. If desired, the antibody molecules can be isolated from the mammal, e.g., from the whole blood, plasma or serum, and further purified from the plasma or serum of the immunized mammal by conventional techniques. Conventional harvesting techniques can include plasmapheresis, protein A chromatography, among others. Such polyclonal antibody compositions may themselves be employed as pharmaceutical compositions of this invention.

Alternatively, antibody producing cells may be obtained from the mammals and used to prepare other forms of antibodies and ligands, e.g., monoclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, ligands produced by screening phage displays, antibody fragments and mixtures thereof, and synthetic

antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies and fully human antibodies. Preparative techniques for generation of these types of ligands are known and the ligands themselves may be generated using the disclosed amino acid sequences of the PLS3 epitope and optional immunogens. See, e.g., Kohler and
5 Milstein 1975 *Nature*, 256:495-497; Kozbor *et al*, 1983 *Immunol. Today*, 4:72; Cole *et al*, 1985 *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96; Harlow *et al.*, *Antibodies A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988; Queen *et al.*, *Proc. Nat'l. Acad. Sci. USA*, 86:10029-10032 1989; Hodgson *et al.*, *Bio/Technology*, 9:421 1991; International Patent Application No. PCT/GB91/01554,
10 International Patent Publication No. WO92/04381 and International Patent Application No. PCT/GB93/00725, International Patent Publication No. WO93/20210).

Other antibodies to the PLS3 epitope may be developed by screening a recombinant combinatorial immunoglobulin library (e.g., antibody phage displays) with the epitope of this invention to isolate immunoglobulin library members that bind to the
15 PLS3 peptide (W. D. Huse *et al.*, *Science*, 246:1275-1281 1988). Kits for generating and screening phage display libraries are commercially available, e.g., Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01; Strategene Phage Display kits, etc. See, e.g., US Patent No. 5,223,409, International Patent Publication Nos. WO92/09690, WO90/02809, etc. Chimeric antibodies may similarly be
20 developed using known techniques (Morrison *et al*, 1984 *Proc. Natl. Acad. Sci. USA*, 81:6851; Takeda *et al*, *Nature*, 313:452 1984, among others). Chimeric antibodies are molecules in which different portions are derived from different animal species. Single chain antibodies may also be prepared by conventional methods (see, e.g., US Patent Nos. 4,946,778 and 4,704,692) using the variable portions of the polyclonal or
25 monoclonal antibodies produced according to this invention. Antibody fragments, such as the Fab, F(ab')₂ and Fv fragments and libraries thereof may also be employed in various aspects of this invention.

In other embodiments of this invention, the ligand is a nucleic acid molecule. For example, a nucleic acid probe is readily generated to bind to the nucleic acid
30 sequences encoding the epitope sequences identified above or other PLS3 specific sequences. Such an "antisense" sequence as used herein is intended to encompass a single-stranded, partially single stranded or double stranded compound that is

sufficiently complementary to the nucleic acid sequence encoding the above-defined sequences, to be specifically hybridizable thereto. Such a sequence may hybridize completely to the epitope, i.e., be 100% complementary. Alternatively, the sequence may hybridize with less than 100% avidity, but sufficiently to identify the epitope of PLS3 from non-PLS3 sequences. Alternatively, such a sequence may hybridize over one or more segments such that intervening or adjacent segments of the antisense sequence are not involved in the hybridization event (e.g., a loop structure or hairpin structure, such as a ribozyme).

In certain embodiments of this invention, the ligand, e.g., antibody or nucleic acid molecule, of this invention is desirably associated with, or conjugated to, a detectable label. The label on the reagent may be selected from the many known diagnostic labels, such as radioactive compounds, fluorescent compounds and proteins, colorimetric enzymes, etc. In one embodiment, the label can be a colorimetric enzyme, which upon contact with a substrate produces a detectable color signal. As another example, fluorochromes are commonly used labels for diagnostic reagents. Commonly used fluorochromes include fluorescein isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin (APC), and also include the tandem dyes, PE-cyanin-5 (PC5), PE-cyanin-7 (PC7), PE-cyanin-5.5, PE-Texas Red (ECD), rhodamine, PerCP, fluorescein isothiocyanate (FITC) and Alexa dyes. Any fluorochrome may be employed, include those excitable by radiation in the red, blue or green wavelengths or combinations thereof. All of these fluorescent dyes are commercially available, and their uses known to the art. Still other fluorescent dyes may be available from other sources or may be developed in the future. Such dyes are anticipated to be useful in the compositions and methods of this invention.

Methods for coupling or associating the label with the ligand are similarly conventional and known to those of skill in the art. Known methods of label attachment are described (see, for example, Handbook of Fluorescent Probes and Research Chemicals, 6th Ed., R.P. Haugland, Molecular Probes, Inc., Eugene, OR, 1996; Pierce Catalog and Handbook, Life Science and Analytical Research Products, Pierce Chemical Company, Rockford, IL, 1994/1995). Thus, selection of the fluorochrome label(s) and coupling methods do not limit this invention.

Ligands of this invention are usefully assembled into kits, which also contains miscellaneous reagents and apparatus for reading labels, e.g., certain substrates that interact with an enzymatic label to produce a color signal, etc., apparatus for taking blood samples, coated solid supports, miscellaneous substrates and apparatus for evoking or detecting the signals provided by the labels, conventional apparatus for taking blood samples, as well as appropriate vials and other diagnostic assay components, and suitable packaging. Thus an embodiment of this invention is a diagnostic kit for use in diagnosing CTCL, which contains a ligand of this invention as well as other conventional diagnostic kit components. One of skill in the art may also readily select other conventional diagnostic components for this kit.

Such kits and reagents may be employed in a method for detecting the presence of PLS3 in lymphoid cells.

In addition to their use as diagnostic markers, such ligands, preferably antibodies may be coupled with a therapeutic protein, such as a toxin by conventional techniques and employed in a therapeutic method for killing the tumor cells. In this embodiment of a composition of this invention, exemplary conventional therapeutic proteins include toxins such as diphtheria toxoid and tetanus toxin. One of skill in the art can readily select an appropriate therapeutic protein for delivery to the cancer cell via the above-noted ligands. Such antibody-toxin complexes may be used by administering an effective amount of the complex to a patient with CTCL. The ligand targets the toxin to the PLS3 epitope and can be used to kill the cell.

The genes listed in Table 1, Column A, above provide are the best candidates for making additional ligands useful in diagnosis and therapy of CTCL.

EXAMPLES

The invention is now described with reference to the following examples. These examples are provided for the purpose of illustration only and the invention should in no way be construed as being limited to these examples but rather should be construed to encompass any and all variations that become evident as a result of the teaching provided herein.

EXAMPLE 1: ANALYSES OF PBMC FROM PATIENTS WITH CTCL

A. Purification of PBMC from CTCL Samples and Preparation of Normal Controls.

PBMC were obtained by Ficoll gradient separation from peripheral blood of both normal volunteers and leukemic phase CTCL (Showe, L. C. *et al*, *Ann N Y Acad Sci*, 795: 413-415, 1996 (Showe I); Gerosa, F., *et al.*, *Clin Immunol*, 92: 224-234, 1999 (Gerosa II)). A total of 48 viably frozen CTCL patient samples with Sezary cells ranging from 5-99% of the lymphocyte population were analyzed. The Ficoll-purified PBMC fraction from high SS patients was 60-95% CD4⁺ malignant cells with a predominantly Th2 phenotype, and in decreasing abundance small percentages of B cells, monocytes and dendritic cells. Th2 skewed PBMC, prepared by culturing for 4 days in IL-4 and anti-IL-12, were used as controls for the high Sezary cell patients, as many characteristics of advanced disease are associated with a Th2 polarized immune response. Under these conditions >95% of the CD4⁺ T cells express the Th2 phenotype (Nakamura, T., *et al.* 1997 *J Immunol* 158:1085-1094; Nakamura, T., *et al.* 1997 *J Immunol* 158:2648-2653; Gerosa II). Th1 skewed PBMC were prepared by culturing in IL-12 and anti-IL4 for 4 days (Gerosa, F., *et al*, 1996 *J Exp Med* 183:2559-2569). CTCL patients are described as high or low Sezary with reference to the blood tumor burden and were selected based on percent circulating Sezary cells regardless of whether erythroderma was also present. All samples were collected with appropriate patient consent and IRB approval. See Tables 2 and 3.

TABLE 2

Patient Code	Survival Time (mos)	% Sezary	Patient Code	Survival Time (mos)	% Sezary
S1042	44	15	S1261	17	34
S1051	102	5	S1271	3	64
S1052	92	8	S1281	69	62
S1061	16	15	S1291	21	60
S1062	10	15	S1301	112	48
S1072	5	97	S1311	84	61
S1082	5	75	S1331	61	46
S1091	73	66	S1341	3	34
S1103	20	99	S1351	1	32
S1111	76	75	S1361	46	67
S1125	3	90	S1381	24	79
S1134	45	75	S1391	67	15
S1143	5	99	S1401	11	39
S1151	4	60	S1411	9	63

S1161	15	90	S4121	64	30
S1182	44	90	S1431	60	22
S1183	24	90	S1441	43	49
S1192	37	90	S1451	51	36
S1201	3	5	S1461	65	24
S1211	3	15	S1471	2	53
S1221	14	32	S1481	25	28
S1231	2	91	S1491	59	83
S1241	51	21	S1492	107	50
S1251	69	37	S1501	43	71

TABLE 3

Control Code	Type
C0022	Th2
C0032	Th2
C0041	Untreated PBMC
C0081	PHA Blast
C0101	Th1
C0102	Th2
C0111	Th1
C0112	Th2
C0172	Tha
C0173	Th1
C0183	Th1
C0186	Th2
C0196	Th2
C0206	Th2
C0211	Untreated PBMC
C0212	Th1
C0213	Th2
C0221	Untreated PBMC
C0222	Th1
C0223	Th2

B. *cDNA Arrays*

5 cDNA filter arrays were purchased from the Wistar Institute Genomics facility. (<http://www.wistar.upenn.edu/genomics/>). Three 2.5 x 7.5 cm nylon filters, HA-01, -02, and -03, carrying a total of 6600 probes for 4500 individual known genes were used to analyze the eighteen high Sezary count (>60% Sezary cells) samples, and twelve samples from healthy controls. The 30 samples were hybridized as a single
10 batch on sequentially printed arrays. An additional 30 low Sezary count samples and eight controls were analyzed only on gene filter HA03. All arrays used in the study

were printed from the same PCR preparations. Reproducibility studies show a >90% correlation between samples hybridized in triplicate. Sequence verified clones were purchased from Research Genetics. Clones for significant genes were sequenced for verification.

5

C. RNA Isolation, Amplification, and Hybridization

Complete protocols can be accessed at <http://www.wistar.upenn.edu/genomics/>. RNA was isolated using Triagent™ reagent (Molecular Research Center) and total RNA samples were amplified (aRNA) using a modified T7 protocol (Van Gelder, R.N., *et al*, 1990 *Proc Natl Acad Sci U S A* 87:1663-1667), accessed at <http://cmgm.stanford.edu/pbrown/protocols/>. The aRNA target (0.5 µg) was labeled with ³³P, 3000-5000 Ci/mM using Reverse transcriptase. Hybridization was in 2.5 ml of Micro-Hyb™ reagent (Research Genetics) at 42°C for 18 hours. HA-01 and HA-03 filters were hybridized with the same labeled target. HA-02 was hybridized separately with the same aRNA preparation. Filters were exposed to a PhosphorImager™ screen for four days, scanned at 50 micron resolution on a Storm PhosphorImager™ apparatus, and visualized using ImageQuant™ software (Molecular Dynamics).

10

15

D. Real-time PCR

The cDNAs were generated from 0.5 µg of aRNA using Superscript II™ reagent (Life Technologies, Inc). Gene specific primers (IDT, Inc., IA) are listed in Table 4. PCR was performed in a Light Cycler™ apparatus (Roche Diagnostics). Cycle parameters were: 94°C, 3 minute hot start and then, 40 cycles of 94°C, 10 seconds; 56°C or 60°C, 10 seconds; and 72°C, 25 seconds. Product specificity was checked by melting curve analysis and gel electrophoresis and relative gene expression levels were determined by comparison with a standard curve and normalized by dividing the relative gene expression by the average expression of three housekeeping genes, SF3A1, CCT3, and MBD4.

20

25

TABLE 4

SYMBOL	FORWARD	SEQ ID NO:	REVERSE	SEQ ID NO:	SIZE (bp)	T _m (°C)
SF3A1	GGATAAGACGGAATGGAAGT	2	AATGGCAGGGACTTGACA	3	271	56
CCT3	AGCTGGGACAGAAAAGGGACT	4	AACAGTGGAAGACGGCAGTT	5	436	56
GATA3	TATCCATCGCGTTTAGGC	6	CCCAAGAACAGCTCGTTTA	7	280	60
ARJ03	ATAGGCCCAATACTTGT	8	ACACTTAATGCACTCGTCA	9	237	60
DUSP1	TGAAGGCAGACACCTAC	10	GCACATTCGGGACCAATA	11	305	60
PLS3	GCTTGACAAAGCAAGAGT	12	GCATCTTCCCTCTCATACC	13	300	60
CDSIW	CCCTGCTATACATAAAGGTG	14	GCTTGTGAGATTGAGAATGAAC	15	241	60
ISG15	GCTTGAGGCCGTACTCCC	16	CAAATGCGACGAACCTCTGA	17	203	60
ITGB1	GCTTCCATATCAGCAGTAAT	18	GTAGAAAGTCGGGACAAAT	19	241	60
CDKN2	DCTGCTGAAGCAAGGTG	20	CAGTGTGACCCTCTTGAA	21	181	60
CCR1	GGGTAAATGGAAATGATGAGT	22	GAGTTGAGACCTAACGAGAAA	23	195	60
JUNB	ACTCTTTAGAGACTAAGTGCG	24	CCACCTCGACGTTTACAA	25	258	60
CYPTB1	TTGGTATATCAAACAGTAAAGGC	26	TCATGTCCAGAACTTAGC	27	321	60
STAT2	TCCTAGAACCTGGATATTTACAAAG	28	GTGTATGCCGGTGTGA	29	197	60
ARJGEF6	TGCTCTCAGATTAACATGGC	30	GGAATACTTTAGTTGATIGCTGAA	31	199	60
SELL	CTCATCATGGGTTGGATTAG	32	CTGCAAGTGACATCTCTTT	33	211	60
CDSA	ATAACAGCATAGTACAACCT	34	GTATGGTACAAGCAATGCC	35	190	60
DPPS	TTGAATTATCCGTCGGG	36	CCTGGTCGTGTTGGTATG	37	280	60
PPIA	CGTAAACCTGGAATAATTCT	38	CTGTGTCTCCTTCGAGGTA	39	197	60
ZNF161	CAGGTCACAATCCCTATTATAC	40	ACACTAGCAGGACTCTTC	41	286	60
SOD1	CCACATAATAAGTGCCATACAG	42	CCTTAAAAGTGTAATTGTGTGTC	43	229	60
ICAM2	AGAAGGTATTCGAGGTACAC	44	GTACACGCTGACGTTG	45	257	60
TNFRST6	ACGTCGTGTGCTAGATTATCG	46	CACGCAGTCTGGTTCA	47	213	60
TNFSF6	AAGGTCTACATGAGGAACT	48	AGCCGAAAAACGTCTGA	49	205	60
LCPI	ATAGAGGGCGTCTTGC	50	CTCACATACACACACACC	51	229	60
IL18	GGATGAATTGGGGGATAGA	52	GTCACACTCACTAGCTAATTT	53	218	56
TNFRST5	CACTATCACAACAATGCTG	54	ACCTTGAAGAACCTCTCAC	55	221	60
TNFSF5	TATACACTCCAAGGCATGTAG	56	CTCCCCATTTCCTTCTG	57	279	60
MGAM	ATTATTCCTCCACCGC	58	TGAACTGGGTCCATGAT	59	187	60
CD44	ATGGTTATGTTTCCAACGG	60	GTGGACTCAACGGAGAGG	61	189	56
NFKDIA	GTACAGCATTACAGGAGGG	62	CTCACCTTGTGGGGTT	63	198	56
NFKB1	TACAGGTCCAGGGTATAGC	64	GCTCTGTGTTTCAATAACT	65	203	56
MBO4	CACATCTCTCCAGTCTGC	66	CGACGTAAAGCCTTTAAGAA	67	207	56
CDID	TGAGACGCCTCTGTTTC	68	ACACCTCAAATACATACCTACT	69	189	60
CX3CRI	AGTAATGGCAAGTAAATTGGG	70	CAAATAGTGCTCGCTTTCT	71	201	60
ILIR2	AGGACACAGCGGTAATAG	72	CCATTGAGCCTCAGAGT	73	269	60
IPFSF10	ACGTGTACTTTACCAACGA	74	ATGCCCACTCCTTGAT	75	380	60
ILIR1	ATGGCTCAATACCTTTTATTC	76	AAAACCTTTAATGCCITCCAC	77	198	60

E. Array analysis

- 5 The data for each array was analyzed with ArrayVision™ software (Imaging Research), using the median pixel for each spot and local background correction. Expression values for each array were normalized by the background corrected signal median spot of the array and then transformed to corresponding z-scores for clustering. T-tests, frequency analysis, and permutations were done using Excel™ software and

Visual Basic™ software. Dynamic range of signals was, on average, 10-20,000 (normalized median density of 0.15 to 3000). The detection limit for these conditions and arrays, calibrated by quantitative PCR (QPCR) with a plasmid standard, is approximately 0.03 molecules per cell.

5

F. Penalized Discriminant Analysis

Supervised classification of genes and arrays was carried out using penalized discriminant analysis (PDA), as described in Hastie *et al*, 1995 and Raychouderi, 2001, cited above, and as provided by CLEAVER (Classification of Expression Array Version 1.0: <http://classify.stanford.edu/>) internet site. This program, a variant of linear discriminant analysis, classifies unknown samples based on the information from a two class training set used to identify genes whose expression levels have a maximum variation between the training classes, and a minimal variation within each training class. PDA adds a "penalty" in the form of a diagonal matrix, which is added to the covariance matrix, allowing the latter to be inverted even though genes greatly outnumber samples. The exact value of this penalty (between 100 and 1000) did not significantly alter the ranks of the informative genes. The implementation of PDA used in the CLEAVER™ program limits the number of genes used in training and subsequent classification to the 500 genes, whose expression best distinguishes between the positive (patient) and negative (control) examples. Although more genes are input to the program and are correlated with the training classes, no more than 500 are used in classification. The program outputs two sets of results: a positive or negative score that indicates how well a sample is assigned to a particular class and a "predictive power" assigned to each gene as a measure of its ability to discriminate the two classes.

25

After demonstrating 100% cross-validation accuracy with a complete gene set, a t-test filter of $p < 0.1$ was added to the input data to help to identify the best classifiers by eliminating genes which contribute a disproportionate amount of noise to the analysis.

30

G. Selection of Correlated Gene Clusters

Clusters of genes whose expression patterns among patients were highly correlated with selected seed genes in a microarray data set were selected as follows.

An average expression profile for the seed is calculated as a weighted sum of the gene expression values for all genes that have a correlation coefficient with the seed gene higher than 0.7. The correlation coefficients are used as weights for this calculation. Then the correlation coefficients between the computed average profile and each gene in the data set are determined. The correlation coefficients are binned, and their distribution determined to permit assignment of genes to the cluster that are above a selected correlation coefficient. Each gene in the data set is used as a seed. When this analysis is repeated on permuted expression values for each gene, there is no correlation over 0.7.

H. Results

The eighteen samples from seventeen patients used for the initial studies were selected to have high Sezary cell counts, ranging from 60-99% of total circulating lymphocytes. Two samples from patient S118 were taken one year apart. All patients had ratios of CD4⁺ to CD8⁺ T-cells greater than ten. This extreme departure from the normal 3:2 CD4⁺/CD8⁺ ratio is characteristic of leukemic phase disease.

Th2 skewed PBMC were selected as controls for the high Sezary cell patients as many characteristics of advanced disease are associated with a Th2 polarized immune response, including: (1) high serum levels of IgE and IgA, (2) increasing serum levels of anti-inflammatory cytokines IL-4, IL-5, and IL-10, (3) a general loss of T-cell responsiveness to mitogens and antigens (Vowels, B.R., *et al*, 1992 *J Invest Dermatol* 99:90-94), (4) lack of expression of the $\beta 2$ chain of the IL-12 receptor (Showe *et al*, 1999, cited above). For the discriminant analysis of samples with low Sezary cell counts, data was included for untreated PBMC and Th1 skewed controls where indicated, in order to provide greater diversity within the control population.

To find candidate differentially expressed genes, normalized expression levels were compared between eighteen high Sezary cell samples and nine Th2 skewed controls. The data set was first analyzed gene-by-gene with a univariate t-test. FIG. 1A shows the number of significant genes (SG) detected as a function of p-value. At $p < 0.01$, 385 unique genes were found to be significantly upregulated or downregulated in patients relative to the controls, rising to 1400 genes at $p < 0.10$. To estimate the number of false-positive genes, the experimental and control labels were permuted (10,000 times); t-tests were performed on each permutation, and the

number of “significant genes” that would arise by chance if patients and controls were drawn from the same population was determined. The median number of these significant genes, which are false positives relative to the original data set, was calculated for each permutation at each p-value cut-off as shown (FP).

5 The median number of false positives at $p < 0.01$ was 27, or approximately 8% of the 385 significant genes at that p value (see line FP). The number of true positive genes, the number of observed significant genes minus the number of false positives (SG-FP), rises to a near-constant value of approximately 1000 at $p=0.15$. This ignores the number of false negative genes arising in the observed data that
10 would increase the number of truly positive genes. If this value is compared to the number of true positives at a given p-value, and if only the genes detected at $p < 0.01$ are considered, many potentially “significant genes” would be missed (MG in FIG. 1A).

 If stringency is increased and higher percentiles of permutations are used (60-
15 95th) and these values are subtracted from SG, then fewer and fewer true positive genes are reported (FIG. 1B). However, even if the 95th percentile of the permuted samples is used, 300 true positive genes are still identified at $p < 0.01$. Of the 385 differentially expressed genes identified at $p < 0.01$, average changes in expression relative to Th2 controls range from 25-fold for overexpression to 7-fold for underexpression.

20 The treeview of FIG 2 was prepared as described in Eisen, M.B. *et al*, 1998 *Proc Natl Acad Sci U S A* 95:14863-14868 showing the variation in expression of the 135 $p < 0.01$ significant genes that are either upregulated or downregulated >2-fold in eighteen high tumor burden patients was compared to nine Th2-skewed controls. The significant genes are listed on the right side of the tree view using gene symbols from
25 Source (<http://genome-www5.stanford.edu/cgi-bin/SMD/source//BatchSearch>). The pale cluster identifies genes which are downregulated and the dark cluster genes which are upregulated in patients versus controls. Values for fold increases or decreases (-) precede the gene symbols.

 The most highly changed expression levels are for dual specificity phosphatase
30 1 (DUSP1), 25-fold overexpressed, and CD40 (TNFRSF5), 7-fold underexpressed. Other genes overexpressed more than 10-fold in patients include versican, a cell surface protein that binds L-selectin and regulates chemokine function (Hirose, J. *et al*, 2001 *J*

Biol Chem 276:5228-5234.); T-plastin (PLS3), an actin bundling protein not normally expressed in T-cells (Lin, C.S., *et al*, 1999 *DNA Cell Biol* 18:27-37); and the small GTP-binding protein, RhoB (ARHB), involved in cytoskeleton reorganization and signal transduction (Ridley, A.J. 2001 *Traffic* 2:303-310; Small, J.V. *et al*, 1999 *Curr Opin Cell Biol* 11:54-60; Narumiya, S. *et al*, 1997 *FEBS Lett* 410:68-72). In addition, message for the receptor for IL-11 (IL-11R) and the TNF related cytokine, TRAIL (TNFSF10) are significantly increased. IL-11 is a strong inducer of Th2 differentiation and signals the down-regulation of IL-12 (Bozza, M. *et al*, 2001 *J Interferon Cytokine Res* 21:21-30), both characteristic of Sezary cells. Underexpressed genes include CD26 (DPP4), whose loss has been suggested to be a strong marker for CTCL (Jones, D., *et al*, 2001 *Am J Clin Pathol* 115:885-892). Both CD8⁺ α and CD8⁺ β message levels are also down, consistent with the observed decrease in CD8⁺ T-cell numbers (Bernengo, M.G., *et al*, 1998 *Ann Oncol* 9:857-863) with advancing disease. Other significantly downregulated genes include the IL-1 receptors, signal transducer and activator of transcription 4 (STAT4), and the IL-2 receptor beta chain.

EXAMPLE 2: VALIDATION OF ARRAY RESULTS USING QUANTITATIVE REAL-TIME PCR.

To determine the accuracy of changes in gene expression reported by the arrays in Example 1, selected genes were assayed by quantitative real-time PCR (QPCR) for the eighteen high Sezary cell samples and nine Th2 controls. The direction of change by PCR was in agreement for every gene tested. Of 32 genes tested, only one gene, PLS3, showed an important difference in the two assays (500-fold up by QPCR and only 14-fold up by array, probably attributable to some cross-hybridization which raised the array control values.

Over the remaining 31 genes, for approximately 75%, the two ratios agreed within a factor of two, the average of the microarray ratio to the QPCR ratio was 0.70, and the median was 0.61. The comparison of the PCR and microarray assay in Table 5 shows that the arrays give a highly reliable estimate of the direction of change in gene expression with a tendency to underestimate quantitative differences.

TABLE 5: Verification of Array Using Quantitative Real-Time PCR

Genes		Array Experiment			P value*	Real-time Experiment			P value*
Name	Symbol	Th2 Mean + SD	Patient Mean + SD	Ratio		Th2 Mean + SD	Patient Mean + SD	Ratio	
Dual specificity phosphatase 1	DUSP1	0.2+0.1	3.9+ 2.9	25	<0.001	0.1+ 0.1	1.8+1.5	31	<0.001
Plastin T	PLS3	0.7+ 0.2	10 + 9.7	14	<0.001	0.01+0.01	3.5+ 6.4	479	0.034
Rho B	ARHB	0.3+ 0.2	3.4+ 3.7	11	0.002	0.2+ 0.1	1.6+ 1.6	8	0.002
JunB	JUNB	1+0.3	4.9+3.2	5	<0.001	0.3+0.2	3.1+2.9	10	<0.001
Integrin β 1	ITGB1	1+ 0.7	4.6+ 5.4	4.5	0.013	0.1+ 0.1	1.4 +1.5	12	0.003
TRAIL/APO-2 ligand	TNFSF10	0.7+ 0.2	3+ 3.5	4.2	0.015	0.3+ 0.1	1.7+ 1.4	6	<0.001
CX3C receptor 1	CX3CR1	0.7+ 0.4	3.4+ 3.4	4.5	0.006	0.3+ 0.2	2.1+ 2.4	8	0.004
Interferon-stimulated protein	ISG15	1 + 0.3	4.+ 4.0	4.2	0.005	0.4+ 0.3	3.4+ 4.2	9	0.009
Cyclin-dependent kinase I 2D	CDKN2D	1 + 0.4	2.8+ 1.6	2.7	<0.001	0.4+ 0.1	1.7+ 0.9	4.3	<0.001
Intercellular adhesion mol. 2	ICAM2	3.7+ 1.2	9.8 +3.8	2.7	<0.001	0.4+ 0.2	1.4+ 0.8	3.3	<0.001
CD1D	CD1D	0.4+ 0.1	0.9+ 0.7	2.6	0.005	0.1+ 0.1	2.4+ 2.5	16	0.001
GATA3	GATA3	1.3+ 0.6	3.2 +1.6	2.5	<0.001	0.3+ 0.2	2.2+ 1.5	7	<0.001
Selectin L	SELL	5.4+ 2.2	10.8+ 4.6	2	<0.001	0.6+ 0.4	1.8+ 1.1	2.8	<0.001
CD44	CD44	13.3+3.7	7.3+3.0	-1.8	0.001	2.3+ 2.3	1 + 0.6	-2.3	0.188
CD8 α	CD8A	1.4+ 0.7	0.6+ 0.3	-2.2	0.01	1.3+ 0.7	0.1+ 0.1	-14	<0.001
Chemokine (C-C motif) Rec. 1	CCR1	6.8+ 3.6	2.7+ 4.4	-2.5	0.019	1.4+ 1.0	0.9 + 1.4	-1.6	0.277
Signal trans. & act. of trans. 4	STAT4	2.7 + 1.6	0.7 + 0.8	-3.7	0.005	1.4+ 0.4	0.3 + 0.3	-4.5	<0.001
Interleukin 1 receptor type II	IL1R2	2 + 0.8	0.5 + 0.2	-3.8	<0.001	2.2 + 1.3	0.1+ 0.1	-26	0.001
CD8 β	CD8B	3.7 + 2.2	0.7 + 0.3	-5	0.004	1.7 + 0.8	0.4 + 0.3	-4.6	<0.001
CD26	DPP4	1.5 + 0.6	0.2 + 0.1	-7	<0.001	1.5+ 0.9	0.1+ 0.1	-19	0.001
CD40	TNFRSF5	3.3 + 1.8	0.5+ 0.3	-7	<0.001	1.9 + 0.9	0.3 + 0.3	-6	<0.001
Cytochrome	CYB1B1	15	1.1 +	-13	0.015	1.7 +	0.2 +	-6	0.001

P450 1B1		+13.4	1.0			1.3	0.2		
Interleukin 1 receptor type I	IL-1R1	4.0+ 3.9	0.6 + 0.2	-18	0.032	2.1+ 1.8	0.2+ 0.2	-11	0.014
I κ B α	NFKB1A	7.2+ 2.9	9.5+ 6.2	1.3	0.193	0.5+ 0.4	1.1+ 1.6	2.2	0.135
Rac/Cdc42 GEF 6	ARHGEF6	5.9 2.3	7.8+ 2.4	1.3	0.066	7.2+ 2.9	7.2+ 2.9	2.2	0.013
Zinc finger protein 161	ZNF161	2.8+ 0.7	3.1+ 0.5	1.1	0.366	1.3+ 1.0	1.5+ 1.2	1.2	0.586
Superoxide dismutase 1	SOD1	14 + 5.2	14.8+5.8	1.1	0.737	1.1+ 0.9	2.4+ 2.4	2.2	0.051
Cyclophilin A	PPIA	10.6+ 3.6	10.7+ 3.6	1	0.939	1+1.3	1.6+ 1.2	1.7	0.207
NF κ B1 (p105)	NFKB1	2.7+ 0.8	2.8 + 1.4	1	0.875	0.7 + 0.6	0.5+ 0.3	-1.4	0.408
Maltase-glucoamylase	MGAM 1	1+0.4	0.9+ 0.4	-1.2	0.368	0.8+ 1.2	1.3+ 1.3	1.7	0.314
Fas	TNFRSF6	1.1+0.5	0.9+0.4	-1.2	0.374	0.7+0.6	0.6+0.6	-1.2	0.631
Plastin L	LCP1	40.4+ 25	24.0+ 11	-1.7	0.095	0.9+ 0.4	0.9+ 0.3	-1	0.958
CD40 ligand	TNFSF5	na	na	na	na	0.3+0.1	1.5+2.0	6	0.015
IL-18	IL-18	na	na	na	na	1+ 0.9	1.5+1.0	1.5	0.22
Fas ligand	TNFSF6	na	na	na	na	12. +0.6	0.5+0.5	-2.4	0.014

Determined by Student's *t* test.

EXAMPLE 3: EXPRESSION PROFILES OF A SMALL NUMBER OF GENES IDENTIFIED BY PENALIZED DISCRIMINANT ANALYSIS CORRECTLY CLASSIFY HIGH SEZARY PATIENTS AND NORMAL CONTROL SAMPLES

5

PDA, as implemented by CLEAVER was used to identify genes with the highest power to correctly distinguish patients from controls. To identify the best genes for distinguishing the two sample classes, the PDA program was trained on the eighteen high Sezary cell samples versus nine Th2-skewed and three untreated controls.

10

Crossvalidation of the samples in these two classes is 100% accurate.

15

To select the best features for classification a $p < 0.10$ p-value cut-off was applied to eliminate genes that contribute a disproportionate number of false positives. The genes identified by t-test at $p < 0.10$ were used rather than the 385 $p < 0.01$ gene set, in order to include genes with higher variance that might be good class predictors. To assess the total number of genes that were good classifiers, the genes were ranked according to the absolute value of their assigned predictive power. When the logarithm of the predictive power was plotted against the logarithm of the

rank, 200 genes were found to have a faster rise in predictive power than in rank. According to Zipf's law (Zipf, G. 1949 *Human Behavior and Principle of Least Effort: An Introduction to Human Ecology* Addison Wesley, Cambridge, MA), these 200 genes are expected to most effectively differentiate patients from controls.

- 5 As few as four of these genes, for example, either
- 1) STAT4, TOB1, CD26 and TRAIL, or
 - 2) STAT4, TOB1, SEC61A1 and GS3686,
- can be used for correct classification.

10 FIG. 4 lists the 90 best classifiers (e.g., most informative genes) that discriminate high Sezary patients from normal controls using PDA. Rank is a measure of the predictive power and ratio is the average fold change between patients and controls, minus indicates down-regulation in patients. It is important to note that half of the 90 genes are in the $p < 0.10$ data set, but not the more restricted $p < 0.01$ data set.

15 *Classification of Sezary Patients with Low Tumor Burden.*

 Having achieved a 100% cross-validation on the high blood tumor burden data set, PDA was used to classify a holdout set of 27 patient samples with 5-53% circulating Sezary cells, and eight additional controls, including 1 untreated PBMC and seven Th1 skewed PBMC. The high Sezary cell samples were again used as the

20 training set. Since the additional patients and controls had been analyzed using only the genes on human array HA-03, the 500 genes from HA-03, which were in the $p < 0.10$ data set, were used to train the PDA. To determine the minimal number of genes needed to classify the holdout set, the up and down regulated genes with lower predictive powers, as determined by the training set, were progressively removed.

25 From 40 to 500 genes, the classification is virtually identical, and classification is 100% accurate (data not shown). The 40 genes remaining are listed in Table 6.

 When the classification set is reduced to twenty genes (i.e., the top 20 genes listed in Table 6), one patient sample, S139.1, is classified as a control. This patient was subsequently found to suffer from a peripheral T-cell lymphoma resembling

30 Kimura's disease (Gilliam, A.C., and G.S. Wood. 2000 *Semin Cutan Med Surg* 19:133-141), not SS. If the number was reduced to eight genes, one normal control C022-1 is misclassified. To determine whether the twenty genes with the highest predictive

powers were uniquely required for accurate classification, the procedure was reversed, and genes with the highest, rather than the lowest, predictive power from the 500 gene data set were sequentially removed. The best 85 genes, equally divided between positive and negative classifiers, can be removed before classification becomes less than 100% (data not shown). This shows that although many more genes are required, the 300 genes with lower predictive powers can still classify accurately.

FIG. 5 shows the classification when the number of controls in the training set was reduced to four Th2 and two untreated PBMC controls. This permitted inclusion of more of the Th2 controls in the test set. The 40 genes identified in the training set with fewer controls also perfectly classify the additional 27 CTCL patients and fourteen normal controls. If the number of classifiers was reduced to the top twenty genes, once again the Kimura's disease sample fails to classify as a CTCL patient.

The list of the 40 best classifier genes used for the classification is shown below in Table 6. Genes are listed top to bottom, sorted by the value of their predictive power.

TABLE 6

Genes Down-Regulated in Patients	Genes Up-Regulated in Patients
STAT4	ARHB
MGAM	TNFSF10
IL1R2	CD1D
IL1R1	DUSP1
TNFRSF5	PLS3
SCYA4	RBL2
NINJ1	CYP24
NFKB2	PDE6C
ST13	SPK
ELK3	GATA3
CYP1B1	CDKN2D
GTF2E1	NNJ2
APOE2	DTR
KLRC1	SIRT5
BCL7A	ING1
ABL1	MAOB
FABP6	AKR1C2
IL2RB	PK-120
POU6F1	EST
AMFR	XPC

EXAMPLE 4: EXPRESSION PATTERNS FOR CLUSTERS OF GENES ARE FOUND TO VARY COORDINATELY AMONG CTCL PATIENTS.

Among the differentially expressed genes in the CTCL patients, overexpressed genes exhibit much greater patient-to-patient variability in expression levels than underexpressed genes do. This is evident from FIGS. 2A–2B. The alternating expression levels across patient samples for some of the top classifiers and highly differentially expressed genes appeared to be highly correlated, for example, RHOB with DUSP1. These correlations are important for the identification of patient subsets. Therefore, clusters of genes with highly correlated expression among the upregulated genes in the $p < 0.10$ data set were identified.

To identify an expression cluster for a *seed* gene, an average profile for this gene was first calculated, and included all the genes that had a correlation with the average profile that was above 0.7 in the cluster. The rationale for using 0.7 as a cutoff is provided in FIG. 6, which compares the degree of correlation of expression values among genes in the observed data set with that in a data set in which the expression values for each gene were randomly permuted. FIG. 6 shows the mean and 95th percentile distributions of correlation coefficients, on a data set containing only upregulated genes from $p < 0.10$ data set and the same distributions calculated on the same data set but with the expression values randomly permuted. The distributions of correlated genes obtained on the permuted data set show no genes with correlation coefficients above 0.7, even for the 95th percentile of permutations. The distributions obtained on the real data set have a substantial number of genes with correlation coefficients above 0.7, suggesting that they do not belong to a cluster by chance.

Correlated clusters were calculated for all 1065 upregulated genes in the data set and only three clusters were identified that included a significant number of members with correlations greater than 0.7. Many of the genes included are genes from the $p < 0.01$ data set. The cluster identified using the RhoB as the seed gene contains DUSP1, v-JUN, IEP, JunB, JunD, and DNAj, all immediate early genes. The cluster identified with farnesyl diphosphate farnesyltransferase 1 (FDFTase1) as the seed gene includes small GTP binding proteins, vav2 and cdc42, which are modified by this enzyme, but not RhoB which is also modified by FDFTase1. Finally there is a cluster with CD1D including caspase 1, versican, and S100A12, all included in the $p < 0.01$ gene list.

EXAMPLE 5: PATIENTS THAT SURVIVE LESS THAN 6 MONTHS FROM THE TIME OF SAMPLING DEFINE A DISTINCT STATE OF THE DISEASE.

This example evaluated whether disease progression could be correlated with gene expression patterns. For this analysis, the seventeen high Sezary cell patients
5 were divided into two groups based on observed survival. Six patients that died between one and six months from the time the sample was taken were designated short term survivors (ST); eleven patients who survived more than 12 months (24 months to >5 years) were designated long-term survivors (LT). T-test analysis of the gene expression profiles for the two groups calculated on the 4500 genes analyzed, identified
10 400 genes that were differentially expressed at $p < 0.01$. Based on 1500 permutations of the patient labels, there is less than a 1% probability that this number of differentially expressed genes could occur by chance.

PDA was applied to the set of 1400 genes that were identified as being differentially expressed at $p < 0.10$ to find the most informative genes for distinguishing
15 between the ST and LT patients. The 38 genes with highest predictive power (i.e., whose expression levels best distinguish short-term (ST) from long-term (LT) CTCL survivors and the high tumor burden patients that they classify) are shown in the TreeView dendrogram of FIG. 7.

The analysis was then extended to include patients with low Sezary cell counts, again using the data from only the HA-03 array. The 48 samples in this data set were
20 divided into three groups based on survival: 12 ST (1-6 mos.), 25 LT (more than 40 mos.), and 11 samples with intermediate (MT) survivals (12-40 mos.). The ST and LT groups were used as a training set and the twelve MT samples were withheld for classification.

25 When all the genes on the HA03 array were used for training, the accuracy of cross validation between ST and LT survivors was greater than 90%, and the MT patients were classified as LT survivors (See FIG. 8). This suggests that the patients that survived less than six months are significantly different from those that survive twelve months or longer.

30 To determine which genes were the best class predictors, twenty jack knife permutations of PDA were performed on the 37 LT and ST patients with the 2032 genes on HA03. For each permutation a random 2/3 of each class was chosen for

training and the remaining 1/3 for validation. The predictive powers of the genes were ranked for each permutation, and the average and standard deviation of the ranks determined. The 40 genes with the highest mean ranks, and the lowest standard deviation of ranks were again used for twenty jack knife permutations of PDA (see
 5 Tables 7 and 8 below). The results of 20 classifications using these 40 genes are shown in Table 11. The results show the worst, the best, and the average of the 20 classifications. An accuracy of 75% of ST, or 90% of LT means that 1 of the 4 ST, or 1 of 10 LT patients in the test set was misclassified.

TABLE 7

Genes Over-Expressed in LT Survivors	Genes Over-Expressed in ST Survivors
IL2RB	P4HB
TGRBR3	LY64
BCL2	HEHU
TCN1	DAD1
SFTPD	BATF
HLA-DQB1	RPA3
ITIH4	RAD23B
PGDS	FLJ32496
ADRB2	BAX
ICSBP1	CCND2
TCL1A	NRP2
PDCD2	ENG
CHK	HSPE1
HLA-DMB	FKBP5
CDR2	PASK
EIF2B5	IL9
CD1D	TEAD4
PGRMC1	AR
FGF12B	RARB
TRA1	RPIA

10

TABLE 8: Accuracy of Survival Classification Using 20 Permuted Patient Sets

CLASSIFICATION	Short-Term Survival (%)	Long-Term Survival (%)	COMBINED (%)
Lowest	75	90	86
Highest	100	100	100
Mean	91	97	96

This set achieves 100% accuracy in crossvalidation of ST and LT survivors and as few as 10 genes, i.e., the top ten genes in Table 7, five from each column, are

sufficient for 100% accurate cross-validation. Thus a small number of genes can be used to distinguish ST survivors from LT survivors despite the fact they vary widely (5 to 99%) in Sezary cell tumor burden and clinical history.

5 **EXAMPLE 6: DIAGNOSIS OF CTCL PATIENTS WITH HIGH OR LOW
TUMOR BURDENS BY DISCRIMINANT ANALYSIS OF QPCR DATA
(DAPD)**

10 In the previous examples, PDA of microarray data was used to identify a subset of genes that could accurately distinguish between SzS patients with 5-99% circulating tumor cells and normal control samples. The 5 genes used in the analysis of this example were selected from a panel of 20 of these genes identified on cDNA arrays, as having high predictive values for making this distinction. The 5 genes selected, and their expression levels relative to controls based on the array data were:

15 STAT4 (Ratio: -3.7; p=.0004),
CD1D (Ratio: +2.3; p=0.008),
GATA3 (Ratio: +2.6; p=.00008),
TRAIL (Ratio: +4.5; p=0.013), and
PLS3 (Ratio: +13; p=.0007).

20 STAT4 is the only gene down regulated in patients in this panel. Its loss in CD4⁺ SzS cells was shown previously in a small number of patients by Western blotting (Showe, L. C. *et al*, J Immunol, 163: 4073-4079, 1999; Showe II). The remaining 4 genes are all over-expressed in patients relative to controls.

A. Purification of PBMC and Preparation of Samples and Controls

25 Peripheral blood mononuclear cells (PBMC) were obtained by Ficoll gradient separation from peripheral blood of normal volunteers or SzS patients as described in Example 1. Normal control PBMC were either untreated (UT), or were skewed to Th1 and Th2 phenotypes as previously described in Example 1. Th2 skewed PBMC were used as controls for training. SzS cells closely resemble Th2 T-cells, as mentioned above. The UT and Th1 skewed controls were included in validation sets to provide a
30 more diverse panel of control samples to more stringently test the classification.

Patients and controls from five patient/control groups were divided into several groups in order to have an appropriate balance of patients and various types of controls

in both training and validation sets for analysis by microarray and by qPCR (Tables 9 and 10). Training sets were selected from patients with greater than 60% SzS cells, while test sets had patients with 5-62% in order to test the sensitivity of the method.

Group 1 includes 30 samples, 18 patients with SzS cell counts ranging from 60 – 99% of total circulating lymphocytes, 9 Th2 skewed PBMC (Th2) and 3 UT controls. These samples were used to train the LDA for both array and PCR studies. Groups 2 and 3 include 34 and 48 samples, respectively. Both groups include 26 patient samples with 5-62% SzS cells and 8 controls, primarily Th1 skewed PMBC (Th1). These samples were analyzed by arrays and PCR.

Group 3 also includes an additional 14 control samples only analyzed by PCR. RNA samples analyzed in Groups 1,2, and 3 were all T7 amplified (Van Gelder, R. N. et al, 1990 *Proc Natl Acad Sci USA*, 87: 1663-1667). Group 4 includes 16 patients, mostly high SzS cell counts, and 13 controls. These samples are total RNA and were used as a total RNA training set for the samples in Group 5. Group 5 includes 13 patients and 10 controls. It includes an independent set of patient and control samples derived from 3 separate sources with coded identities. PHA indicates that cells were PHA treated for 4 days. N/A means that SzS cell counts were not available.

TABLE 9: Patient Sample Groups 1-5

Patient	%Sezary Cells	Group				
		1	2	3	4	5
S104.2	15	-	+	+	-	-
S105.2	8	-	+	+	+	-
S106.2	15	-	+	+	-	-
S107.2	97	+	-	-	+	-
S109.1	86	+	-	-	+	-
S110.3	99	+	-	-	-	-
S111.1	75	+	-	-	+	-
S112.3	N/a	-	-	-	+	-
S112.5	90	+	-	-	-	-
S113.4	75	+	-	-	+	-
S114.3	99	+	-	-	+	-
S115.1	60	+	-	-	+	-
S116.1	90	+	-	-	+	-
S118.2	90	+	-	-	+	-
S118.3	90	+	-	-	+	-
S119.2	90	+	-	-	+	-
S120.1	5	-	+	+	-	-
S121.1	15	-	+	+	-	-

S122.1	32	-	+	+	+	-
S123.1	91	+	-	-	+	-
S124.1	21	-	+	+	-	-
S125.1	37	-	+	+	-	-
S126.1	34	-	+	+	-	-
S127.1	64	+	-	-	-	-
S128.1	62	-	+	+	-	-
S129.1	50	-	+	+	-	-
S130.1	48	-	+	+	-	-
S131.1	61	-	+	+	-	-
S132.1	84	-	-	-	-	+
S133.1	46	-	+	+	+	-
S134.1	34	-	+	+	-	-
S135.1	32	-	+	+	-	-
S136.1	67	+	-	-	-	-
S137.1	27	-	-	-	-	+
S138.1	79	+	-	-	-	-
S139.1	15	-	+	+	-	-
S140.1	39	-	+	+	-	-
S141.1	53	-	+	+	-	-
S142.1	30	-	+	+	-	-
S143.1	22	-	+	+	-	-
S144.1	40	-	+	+	-	-
S145.1	36	-	+	+	-	-
S146.1	24	-	+	+	+	-
S147.1	53	-	+	+	-	-
S148.1	28	-	+	+	-	-
S149.1	83	+	-	-	-	-
S150.1	71	+	-	-	-	-
S151.1	N/A	-	-	-	-	+
S152.1	N/A	-	-	-	-	+
S153.2	N/A	-	-	-	-	+
S154.2	N/A	-	-	-	-	+
S155.1	N/A	-	-	-	-	+
S156.1	N/A	-	-	-	-	+
S157.3	N/A	-	-	-	-	+
S158.1	N/A	-	-	-	-	+
S159.1	N/A	-	-	-	-	+
S160.1	N/A	-	-	-	-	+
S161.1	N/A	-	-	-	-	+

TABLE 10: Control Sample Groups 1-5

Control	Type	Group				
		1	2	3	4	5
C002.2	Th2	+	-	-	-	-
C003.2	Th2	+	-	-	+	-
C004.1	UT	+	-	-	+	-
C005.1	UT	-	-	+	+	-

C006.1	UT	-	-	+	+	-
C008.1	PHA	-	+	+	-	-
C010.1	Th1	-	+	+	-	-
C010.2	Th2	+	-	-	+	-
C011.1	Th1	-	+	+	-	-
C011.2	Th2	+	-	-	+	-
C017.2	Th1	-	+	+	-	-
C017.3	Th1	-	+	+	-	-
C017.5	Th2	-	-	+	+	-
C018.1	UT	-	-	+	-	-
C018.3	Th1	-	+	+	-	-
C018.5	Th2	-	-	+	-	-
C018.6	Th2	+	-	-	+	-
C019.4	UT	-	-	-	+	-
C019.6	Th2	+	-	-	-	-
C020.6	Th2	+	-	-	-	-
C021.1	UT	+	-	-	+	-
C021.2	Th1	-	+	+	-	-
C021.3	Th2	+	-	-	+	-
C022.1	UT	+	-	-	+	-
C022.2	Th1	-	+	+	-	-
C022.3	Th2	+	-	-	+	-
C023.1	UT	-	-	+	-	-
C024.1	UT	-	-	+	-	-
C025.1	UT	-	-	+	-	-
C026.1	UT	-	-	+	-	-
C027.1	UT	-	-	+	-	-
C028.1	UT	-	-	+	-	-
C029.1	UT	-	-	+	-	-
C030.1	UT	-	-	+	-	-
C031.1	UT	-	-	+	-	-
C039.1	UT	-	-	-	-	+
C040.1	UT	-	-	-	-	+
C042.1	UT	-	-	-	-	+
C043.1	UT	-	-	-	-	+
C044.1	UT	-	-	-	-	+
C045.1	UT	-	-	-	-	+
C046.1	UT	-	-	-	-	+
C047.1	UT	-	-	-	-	+
C049.1	UT	-	-	-	-	+
C050.1	UT	-	-	-	-	+

All samples were collected with informed consent and IRB approval. The method was validated on a set of samples composed of total, rather than amplified RNA. As a final test, the classification was applied to a blinded set of 23 patient and control samples.

B. RNA isolation and Amplification.

RNA was isolated using Tri-reagent reagent (Molecular Research Ctr., Cincinnati, OH) treated with RNase free DNase I (Boehringer Mannheim, Indianapolis, IN), resuspended in DEPC treated water and concentrations determined spectrophotometrically. RNA integrity was assessed by electrophoresis using SYBR® Green II (Biowhittaker Molecular Applications, Rockland, ME). 78 total RNA samples (44 patients and 34 controls) were subsequently amplified (aRNA) using a modified Eberwine T7 protocol (Van Gelder, 1990 R. N., *et al*, *Proc. Natl. Acad. Sci., USA*, 878:1663-1667). See also the internet site at <http://cmgm.stanford.edu/pbrown/protocols>.

C. cDNA synthesis.

The cDNAs were generated from 0.5µg of aRNA or total RNA using Superscript II reagent for 90 minutes at 37°C in a 15µL reaction. The reaction mixture contained 150 units Superscript II reagent (Invitrogen Corporation, Carlsbad, CA), 1x Buffer (Invitrogen Corporation, Carlsbad, CA), 3.3mM DTT (Invitrogen Corporation, Carlsbad, CA), 1mM dNTP (Promega Corporation, Madison, WI), 67µg/mL oligo-dT (Promega Corporation, Madison, WI), 1µL 10x random decamers (Ambion, Inc., TX.) and aRNA.

D. Quantitative Real Time PCR.

Gene specific primers (IDT, Inc., IA) were designed with the Light Cycler Probe Design Software, Version 1.0 (Idaho Technology Inc., Salt Lake City, UT) from the sequence of spotted cDNA clones. Primer sequences are shown in Table 11.

TABLE 11: Gene Specific Primers for qPCR

Symbol	Forward	SEQ ID NO:	Reverse	SEQ ID NO:	Size (bp)	Temp (°C)
GATA3	TATCCATCGCGTTT AGGC	78	CCCAAGAACAGCTCG TTTA	79	280	60
PLS3	GCTTGACAAAGCA AGAGT	80	GCATCTTCCCTCTCAT ACC	81	300	60
STAT4	TCCTAGAACCTGGN TATTTACAAAG	82	GTGTATGCCGGTGTT GA	83	197	60
CD1D	TGAGACGCCTCTGT TTC	84	ACACCTCAAATACAT ACCTACT	85	189	60
TRAIL	ACGTGTACTTTACC AACGA	86	ATGCCCACTCCTTGA T	87	380	60

PCR was performed in 20 μ l in a Light Cycler Instrument (Roche Diagnostics, Mannheim, Germany). The reaction mixture contained 1 μ l Platinum Taq (Invitrogen Corporation, Carlsbad, CA), 1x Buffer (Invitrogen Corporation, Carlsbad, CA), 2.5mM Magnesium Chloride (Invitrogen Corporation, Carlsbad, CA), 1:20000 SYBR Green I reagent (Biowhittaker Molecular Applications, Rockland, ME), 0.2mM dNTP (Promega Corporation, Madison, WI), 750 μ g/mL BSA (Sigma-Aldrich, Inc.), 0.5 μ M Primer each and cDNA Template. The cycle parameters were: 94°C 3 min hot start, 40 cycles of: 94°C 10sec, 56°C or 60°C 10sec, 72°C 25sec. SYBR Green I fluorescence intensity was measured at the end of each 72°C extension. Product specificity was checked by melting curve analysis and gel electrophoresis.

E. *qPCR Normalization.*

Values for fluorescence intensity of each gene for each subject were reported as the ratio of the determined value to that from a standard curve for each gene of serial dilutions of one subject of the day's tests. The training set was normalized to a unit mean. To compare values from different days, determinations from several subjects were repeated and the average values for each gene used to normalize the values from one day to another.

F. *Linear Discriminant Analysis.*

Supervised classification of samples was carried out using PDA as provided by the CLEAVER website (Hastie, T. *et al*, Annals of Statistics, 23: 73-102, 1995; and Raychaudhuri, S. TIBS, 19: 189-193, 2001) (<http://classify.stanford.edu/documentation.html>). Gene expression values for each patient and control array were ranked, and the ranks were input instead of absolute expression values. To obtain the short list of candidate genes for analysis with qPCR, PDA was applied to ranked microarray expression data consisting of all the genes on the arrays, and the genes with the highest "predictive power" (discriminant weight multiplied by standard variation) were selected, as described in the preceding examples. To obtain discriminant functions for expression values obtained from these few genes by qPCR, PDA was applied to the ranked expression data with no penalty value, reducing the procedure to linear discriminant analysis.

G. *Classification with 5 Genes using LDA and Array Data.*

The ability of the 5 selected genes STAT4, CD1D, GATA3, TRAIL and PLS3,

to correctly classify patients and controls was first tested by applying LDA to the expression data from microarrays, using the array data from the previous examples. When trained on the 18 high tumor burden patients and 12 controls in Group 1 (Tables 9 and 10), LDA was able to correctly classify 28 out of 30 samples. Only one patient and one control were misclassified (93%) by leave-one out cross-validation (FIG. 9A). When tested on the array data from the validation set of 26 low tumor burden patients and 8 controls in Group 2 (Tables 9 and 10), the accuracy of classification is 97% (FIG. 9B). Only one patient with low SzS cell count was misclassified. This shows that the 5 gene classifier trained on high tumor burden patients can also identify low tumor burden patients using LDA and array data.

H. Results: Classification with 5 Genes Using DAPD.

Expression data acquired by qPCR on the same 5 genes from the samples in Group 1 was used to classify patient samples using LDA. When trained on the qPCR data, all but one of the 30 samples is correctly classified by leave-one-out cross validation (FIG. 9C). This is the same patient sample, S123.1 misclassified by the array data. This discriminator was validated on another low tumor burden test set, 26 Sezary patients with Sezary cell counts ranging from 5-62% and 22 normal control samples (Group 3, Tables 9 and 10). Accuracy is 98% and only one patient sample is not classified as CTCL (FIG. 9D). This suggests that genes identified by PDA from cDNA expression arrays are also informative when their relative expression levels determined by qPCR are analyzed by LDA.

I. Results: Classification Using DAPD and total RNA Samples.

Both the array studies and the qPCR studies described above were carried out using aRNA. RNA amplification was necessary for the array experiments because of the limited amount of patient material available. However the DAPD assay would be much simpler if RNA amplification is not necessary. In order to determine whether genes selected using aRNA could also accurately classify qPCR results obtained from total RNA preparations, 29 samples randomly selected from Groups 1, 2 and 3 (16 patients and 13 controls) for which total RNA was available (Group 4) were trained. 28 of 29 samples (97%) were correctly classified by cross validation (FIG. 9E). The same patient sample, S123.1, is once again misclassified. To test this classifier it was applied to total RNA from a blinded set of 13 patient and 10 normal control samples (Group 5)

that were completely independent of the other 4 groups and which had never been analyzed by arrays (FIG. 9F). Twelve of the 13 patient samples and all of the ten controls were correctly classified for an accuracy of 96%.

This example emphasizes the fact that genes selected by array are accurate
5 diagnostic markers for CTCL and are equally accurate when assayed by qPCR. This accuracy is independent of whether aRNA or total RNA is assayed.

To diagnose CTCL, the inventors distinguished patient samples with widely
varying percentages of malignant T-cells from the same type of control cells.
Therefore almost none of the genes tested in these examples show striking and
10 consistent differences between the two classes of samples that are being compared as described in Gordon *et al*, cited above.

Only one of the genes tested herein was uniquely expressed in the malignant
T-cells. PLS3 (tissue plasminogen activator) expression has been confirmed in purified CD4⁺ SzS
cells. In the experiments described herein, PLS3 is expressed only in patient and
15 never in control PBMC, as expression of this gene is normally not found in lymphoid cells. This makes PLS3 an extremely sensitive marker for CTCL. Although its
presence is diagnostic for CTCL in 70% of the patients tested in experiments
described herein, the remaining 30% of patients do not express PCR-detectable levels
of PLS3. This leaves a significant subgroup of patients that must be identified by
20 other means. In fact, DAPD using only 4 genes (excluding PLS3) is as accurate as the 5 gene set.

EXAMPLE 7: MICROARRAY ANALYSIS OF PERIPHERAL BLOOD FROM PATIENTS WITH SOLID TUMOR AND MIXED CELL CANCERS

A. Patients

Solid tumor patients comprised 10 non-small cell lung carcinoma, 2 sarcoma, 2
pancreatic carcinoma, and 1 each esophageal, ovarian, small cell, adrenal, and
mesothelioma, together with 9 normal controls. Approximately 8000 genes had a
complete set of expression values across all patients and controls and these values were
30 used for further analysis.

B. Sample Collection

Sample collection was conducted as follows: Patient and volunteer blood (approx. 10 ml) was collected into Becton-Dickinson Vacutainer™ CPT Mononuclear Cell Preparation tubes. Following centrifugation at 2800 rpm, the buffy coats were removed and washed once with phosphate-buffered saline. The pellets were resuspended in 1 ml of TRIzol™ reagent (Invitrogen) and transferred to 1.5 ml DEPC-treated microfuge tubes. Chloroform (0.2 ml) was added, the samples were vortexed, and centrifuged for 15 minutes at 4°C at 10,000 rpm. Supernatants were transferred to fresh microfuge tubes and 0.5 ml isopropanol was added. Samples were stored at -20°C for at least 1 hour.

Following centrifugation, RNA pellets were washed once with 70% EtOH and resuspended in DEPC dH₂O. RNA concentrations were determined by spectrophotometry (absorbance at 260 nm).

C. RNA Preparation and cDNA Microarrays

RNA samples were amplified using a modified T7 protocol which can be accessed at the Stanford University microarray protocols website. 0.5 µg amplified RNA target was labeled with P-33 dCTP, 3,000-5,000 Ci/mM using reverse transcriptase. Hybridization was in 2.5 ml Micro-Hyb (Research Genetics) at 42°C for 18 hours. Filters HA05 and HA06 were sequentially hybridized to the same target RNA. Filters were exposed to a PhosphorImager screen for 4 days, scanned at 50 nm resolution on a Storm PhosphorImager™ apparatus, and quantitated using ImageQuant™ apparatus (Molecular Dynamics).

Microarrays were purchased from the Wistar Genomics Facility.

D. Results

Analysis of the distance matrix generated using Manhattan or Euclidian distances shows that for most of the samples the most distant member of sample's own group is closer than the closest member of the opposite group (FIG. 10). The only outlier is a lung cancer sample that is positioned exactly halfway between the cancer centroid and control centroid. But this sample is an outlier also relative to the controls: its distance to the control centroid is larger than for any control sample.

The distinction between cancer and control groups using two discriminant methods was confirmed by this data. First, all samples were analyzed with a multiclass shrunken centroids algorithm (Tibshirani, R. *et al*, 2002 *Proc. Natl. Acad. Sci., USA*,

99:6567-6572). In this analysis, all genes and four samples from each of the two solid tumor groups and control group were used for training and the remaining samples were used as a test set. There is no misclassification of any solid tumor as a control or vice versa. Second, cross-validation using PDA between control and cancer groups is 100% accurate.

To estimate the extent of changes in individual patient samples compared to the control group, the following three metrics were used:

- (1) Normalized and shrunken distance to control centroid;
- (2) Predictive scores for each patient obtained with PDA crossvalidation;
- (3) Projection of each sample on the Average Control-Average Cancer vector (see FIG. 11). Metrics 2 and 3 gave similar results.

Several methods were employed to pick out the most informative genes. Although simple t-test between patients and controls identified a substantial number of differentially expressed genes, it was not used as a primary metric because of the substantial variance in the patient group. Indeed, the average distance between cancer samples was observed to be much greater than the average distance between normal controls. The distribution of variance in gene expression is the lowest in the two sets of healthy controls, and the largest in lung adenocarcinomas and a group of "mixed cancers". Therefore, only the variance in the control group was used to normalize the changes in gene expression. Genes were sorted by median Z score in the patient group, relative to the control centroid. Alternatively discriminant loadings from penalized discriminant analysis (PDA) classification of Controls vs Patients was used.

To reduce the variance in the most informative genes, the patient samples that were least advanced in the disease progression as described above were removed. Finally, the genes known to be expressed primarily in cytotoxic T-cells and NK cells were selected and found to be significantly downregulated.

Drastic changes were observed in gene expression from PBMC of cancer patients compared to normal controls. These changes are much greater than both the noise level and biological variability of normal samples. The changes associated with disease progression were variable among patients and presented the main source of variance in the patient group.

Several methods were used to estimate the extent of disease progression. All of the methods used show that lung carcinoma patients have less change and are more variable as a group than the "mixed cancer" group, which contains many different kinds of cancers. The clinical progression of the patients is followed-up to determine if there is a correlation between outcome and level or type of observed changes in gene expression.

The changes of gene expression that are expected in the cancer patients can be associated with either changes in the cell composition or changes in gene expression in the existing PBMC subpopulations. These data suggest that both are taking place and that changes in cell composition are not the main driving factor. As indicated in Table 12 below, NK and Cytotoxic T-cells genes are significantly downregulated. The most significantly downregulated genes according to median Z test are the Growth Genes.

TABLE 12

NK and CTL Cytotoxic Genes	t-test	Median Z score	Growth Genes	t-test	Median Z score
FCGR3A	6.59E-06	-15.2611	PTMA	7.36E-08	-75.4871
GNLY	4.83E-08	-11.7988	HNRPA1	2.78E-10	-37.839
PRF1	2.06E-05	-8.43536	RPL41	1.91E-07	-20.4659
CD8A	3.11E-09	-6.84261	SERPINB6	1.1E-07	-17.6533
CD2	3.44E-06	-6.28723	LDHA	5.38E-13	-15.2629
IL2RG	1.22E-06	-5.50725	TACC1	4.02E-09	-14.7357
GZMK	0.000137	-5.26209	ARPC3	8.56E-07	-12.9633
ITGAM	3.89E-07	-5.25155	CDC25B	2.16E-06	-12.824
PFN1	1.78E-09	-3.64608	CX3CR1	2.23E-06	-12.015
TIA1	0.003585	-3.31555	LDHB	7.67E-10	-11.4787
GZMB	1.93E-06	-2.27722	HNRPA2B1	1.34E-07	-11.3855
IL2RB	0.000158	-2.09404	CDC25A	9.08E-08	-11.2665

EXAMPLE 8: PRELIMINARY ANALYSES OF PBMC FROM PATIENTS WITH LUNG TUMORS AND VARIOUS OTHER TYPES OF CANCEROUS SOLID TUMORS.

To test the characteristics of PBMC from patients with solid tumors, 19 frozen archived samples of these cells were obtained from phase II clinical trials to compare with PBMC from 9 corresponding healthy volunteers (volunteers 1) and 6 of control

PBL from CTCL studies (volunteers 2). RNA from these samples was prepared and compared with expression profiles of the amplified P-33 labeled targets using the methods developed by the inventors in studying CTCL. Each target was probed with two 9,600 gene cDNA arrays carrying a total of 16,000 unique genes, HA05 and HA06 (Wistar Genomics Facility).

Most of the specimens were from patients who had no treatment prior to sampling. However, the supervised classification algorithms detected no significant differences between samples from treated and untreated patients. Ten of the specimens were from patients with non-small-cell lung adenocarcinoma (NSCLC), while the remainder was from a variety of different sarcomas and carcinomas (Table 13).

TABLE 13: Subjects for analysis of gene expression of peripheral blood mononuclear cells from patients with solid tumors.

Subject	Number
Non small cell lung carcinoma	10
Soft tissue sarcoma	2
Pancreatic	2
Esophageal	1
Adrenal	1
Small cell	1
Ovarian	1
Mesothelioma	1
Volunteers 1	9
Volunteers 2	6

Two supervised multivariate classification techniques were used, i.e., multiclass Shrunken Centroids (Tibshirani *et al*, cited above) and 2-class Penalized Discriminant Analysis (PDA) (Raychaudhuri, S. 2001 *TIBS* 19:189-193) to compare the expression profiles of the tumor samples to normal controls, and to each other.

The degree of disease progression was estimated by finding the projection of each sample on an AverageControl-AverageCancer Vector. The calculation was done as follows:

1) Normalized median density values for each spot (NMD) were converted to Ranks and Average vectors were found for each group by averaging the gene ranks in each class;

2) Average Control-Average Cancer vector was found by subtracting each Average Cancer vector from the corresponding Average Control vector;

- 3) Average Control was subtracted from every sample vector;
- 4) Scalar multiplication was performed on Average Control-Average Cancer and Average Control-sample vectors;
- 5) The result was divided by the length of Average Control-Average Cancer vector.

The results are summarized as follows: Using the expression profiles of 12,000 significantly expressed genes, the PDA program was trained to distinguish between the lung cancer patients and one group of healthy donors. When the profiles were tested by cross-validation, the lymphocytes were distinguished from every tumor patient from those of all of the 15 healthy controls (FIG. 12).

Relative down regulation of many genes associated with a pro-inflammatory or Th1 response and genes associated with cell growth and division (energy production, actin remodeling, mitosis) were found in the PBMC from the patient samples during a search for function of genes differentially expressed between cancer patients and controls. There appears to be a general suppression of the cells or genes required for an inflammatory response. See, e.g., Tables 14 through 16. Table 14 below lists inflammatory genes differentially expressed between all cancer patients and controls. The ranks are the position of each gene in the complete list of 12,000 genes, where 1 is the most highly overexpressed and 12,000 is the most highly under expressed in patients vs. controls. Table 15 below lists growth-related genes differentially expressed, i.e., down-regulated, between cancer patients and controls. Table 16 below lists growth-related genes differentially expressed, i.e., up-regulated, between cancer patients and controls.

TABLE 14

Spot	Gene name	Symbol	t-test	Median Z
9055	Fc fragment of IgG, IIIa, receptor for (CD16)	FCGR3A	6.59E-06	-15.2611
2343	Granulysin	GNLY	4.83E-08	-11.7988
6595	Perforin, mRNA sequence	PRF1	2.06E-05	-8.43536
4977	CD8 antigen, alpha polypeptide (p32)	CD8A	3.11E-09	-6.84261
195	CD2 antigen (p50)	CD2	3.44E-06	-6.28723
6976	interleukin 2 receptor, gamma	IL2RG	1.22E-06	-5.50725
4904	granzyme K (serine protease, granzyme 3;)	GZMK	0.000137	-5.26209
7772	integrin, alpha M (CD11b (p170)	ITGAM	3.89E-07	-5.25155

1333	profilin 1	PFN1	1.78E-09	-3.64608
13269	TIA1 cytotoxic granule RNA binding protein	TIA1	0.003585	-3.31555
190	granzyme B (granzyme 2)	GZMB	1.93E-06	-2.27722
8675	interleukin 2 receptor, beta	IL2RB	0.000158	-2.09404

TABLE 15

Spot	Gene Name	Symbol	t-test	Median Z
13563	heterogeneous nuclear ribonucleoprotein A1	HNRPA1	2.78E-10	-37.839
568	ribosomal protein L41	RPL41	1.91E-07	-20.4659
3046	serine proteinase inhibitor, B, member 6	SERPINB6	1.1E-07	-17.6533
14889	lactate dehydrogenase A	LDHA	5.38E-13	-15.2629
5708	actin related protein 2/3 complex, subunit 3, 21kDa	ARPC3	8.56E-07	-12.9633
2532	cell division cycle 25B	CDC25B	2.16E-06	-12.824
2827	chemokine (C-X3-C motif) receptor 1	CX3CR1	2.23E-06	-12.015
3968	lactate dehydrogenase B	LDHB	7.67E-10	-11.4787
1302	heterogeneous nuclear ribonucleoprotein A2/B1	HNRPA2B1	1.34E-07	-11.3855
15426	cell division cycle 25A	CDC25A	9.08E-08	-11.2665
1946	profilin 1	PFN1	6.94E-10	-11.0253
13627	SOCS box-containing WD protein SWiP-1	WSB1	1.9E-08	-10.8725
6518	ARP1 homolog A, centractin alpha	ACTR1A	1.54E-06	-10.7297
3724	G protein-binding protein CRFG	CRFG	7.56E-11	-10.3535
9095	caspase 1,	CASP1	1.07E-05	-10.0506
446	endothelial G-protein-coupled receptor, 1	EDG1	4.35E-10	-9.93481
6556	heterogeneous nuclear ribonucleoprotein H1 (H)	HNRPH1	4.89E-07	-9.90735
16602	F-box and leucine-rich repeat protein 5	FBXL5	2.07E-07	-9.75567
14119	transforming growth factor, beta receptor III	TGFBR3	4.89E-09	-9.5726
8855	SMT3 suppressor of mif two 3 homolog 2 (yeast)	SMT3H2	1.03E-08	-9.46914
12173	ATP synthase, H ⁺	ATP5G3	3.91E-08	-9.36888
1567	actin related protein 2/3 complex, subunit 4, 20kDa	ARPC4	5.79E-11	-9.15806
2676	lamin B receptor	LBR	1.38E-14	-9.04762
4018	heat shock 60kDa protein 1 (chaperonin)	HSPD1	2.68E-07	-9.04721
3637	WAS protein family, member 2	WASF2	1.05E-08	-9.03856
9591	ribosomal protein L23	RPL23	1.42E-06	-8.78879
14881	utrophin (homologous to dystrophin)	UTRN	5.18E-09	-7.94632
19076	CD53 antigen	CD53	5.84E-11	-7.92603
4753	ubiquitin-activating enzyme E1-like	UBE1L	5.48E-07	-7.83583
12810	microtubule-associated protein 1 light	MAP1LC3A	3.87E-06	-7.7265

	chain 3 alpha			
1496	mitogen-activated protein kinase, kinase 1	MAP2K1	5.68E-09	-7.71345
1005	ribosomal protein L10	RPL10	1.42E-08	-7.68992

TABLE 16

Spot	Gene Name	Symbol	T-test	Median Z
1986	synovial sarcoma, X breakpoint 4	SSX4	1.38E-07	7.125294
4926	paired basic amino acid cleaving system 4	PACE4	1.35E-10	5.983932
8805	MAD1 mitotic arrest deficient-like 1 (yeast)	MAD1L1	5.47E-05	5.89851
2971	mitogen-activated protein kinase 10	MAPK10	5.18E-06	5.681738
4660	cyclin K	CCNK	1.09E-07	5.630986
2393	DNA-binding transcriptional activator	NCYM	4.28E-06	5.603383
872	APEX nuclease (DNA repair enzyme) 1	APEX1	1.7E-09	5.424017
487	citron (rho-interacting, serine/threonine kinase 21)	CIT	2.49E-06	5.231441
6061	transducin-like enhancer of split 1	TLE1	2.87E-08	4.780921
7764	ret finger protein	RFP	8.91E-06	4.122543

5 Eleven genes known to be important for a cytotoxic immune response and shown by SAGE analysis to be highly expressed in NK cells and CD8 cytotoxic T-cells (Obata-Onai, A., *et al*, 2002 *Int Immunol* 14:1085-1098) were used alone to perform an unsupervised hierarchical clustering of the patient and control samples. With a single exception, the patient samples cluster apart from the controls. See the treeview cluster

10 of FIG. 13. To test the ability of PDA to distinguish one type of cancer from other cancers, the lung cancer samples were trained against all the other cancers taken as a group. When tested, 80% of the lung cancers were properly classified by leave-one-out cross-validation, as were 7 out of 9 of the mixed cancers (FIG. 14). The results of cross-validation with PDA between Lung Cancer and Mixed Cancer groups are shown

15 in the FIG. 15. The predictive score for each sample was obtained by setting this sample aside and using the rest of the samples for training.

All of the cancer patients were ordered by the projections of their gene profile vectors on the average patient-control axis. The results are shown in FIG. 15. Changes in immune gene expression of each sample are relative to the differences between the

20 average patient and average control.

The “mixed cancers” have higher scores (difference from the controls) than all but three of the NSCLC. Surprisingly, there is greater variance in the lung cancers than there is in the “mixed” tumors, which are more homogeneous. This suggests that the strongest component in distinguishing these two groups of cancers by PDA is degree of immune suppression, rather than tissue of origin. In fact, the genes that make up the “growth repression” signature account for most of the effect seen in FIG. 15.

The strong effect shown by all cancers on immune profiles provides evidence that the method of this invention is a sensitive measure of cancer progression.

EXAMPLE 9: METHODS TO COMPARE CANCER STAGE TO IMMUNE SUPPRESSION

Additional experiments compare cancer stage to degree of immune suppression. This comparison allows prediction of outcome. For example, a high degree of suppression by a small tumor is an indicator of an unfavorable prognosis. To extract information on cell-type or organ-specificity of the cancer, it is necessary to eliminate the stage-specific effects. With larger numbers of cancers of two types, the genes most highly correlated with growth suppression are removed, and then differential analysis with PDA is performed using the remaining genes, which are thereby enriched for those carrying tissue specificity, if such genes exist.

A. Samples.

Patient samples include archived viably frozen PBMC from the University of Pennsylvania, and archived viably frozen PBMC from the Fox Chase Institute for Cancer Research. Results obtained from these collections of PBMC are anticipated to be confirmed using whole blood to determine whether this simpler collection methodology yields similar results.

RNA is extracted using the Tri-Reagent™ system, as described by the manufacturer for either isolated PBMC. The RNA is amplified by a modification of the Eberwine procedure, labeled with 33-P dCTP, and each target is successively hybridized to two 9,600-gene filter arrays HA05 and HA06 (Wistar Genomics facility). Images from the hybridized and washed filters are obtained from phosphorimager screens after 4 days of exposure and quantitated using Imagene™ software (Biodiscovery).

B. Confirmation of informative genes.

Genes determined by statistical analysis (see below) to be the most informative for class distinctions are confirmed by 1) resequencing the clone from the inventors' collection, and 2) performing real time PCR on samples from the appropriate patient and control classes to confirm the difference in expression values estimated from the arrays.

C. Statistical considerations and array analysis.

Expression values are filtered to exclude values less than twice local background on the array, and values on each array are normalized by the median spot value to correct for variations in target radioactivity. Overall correlation between arrays is determined and arrays not correlating with every other array by at least 80 % are repeated. Genes with more than 20% missing values are excluded from analysis, otherwise missing values are interpolated using a published procedure (Troyanskaya, O., *et al.*, 2001 *Bioinformatics* 17:520-52519).

Cancer patients and controls are compared using Penalized Discriminant Analysis (PDA) or PDA as previously described in the preceding examples. Shrunken centroids are used to determine whether any known classes (e.g., for breast cancer, BRCA1, BRCA2, sporadic, ER+, ER-, for lung cancer, adenocarcinoma, squamous cell carcinoma, large cell) have a distinct expression profile. This class is compared separately to controls and samples from patients with other types of cancer in subsequent analyses using PDA.

T-tests are performed between classes to identify individual genes that might serve as biomarkers for a highly specific effect of a tumor on the immune cells. In order to account for false positives derived from multiple testing among informative genes, t-tests are performed on the relevant datasets, and are compared to t-tests on datasets with patients and controls (or two classes of patients) randomly permuted to estimate the possibility that these genes might have been selected by chance. However, the principal means of confirming these classifications is to validate the discriminant functions on independent datasets of patients and controls comprised of new individuals from the various classes of patients.

D. Power analysis.

Previous experience in determining survival of CTCL patients suggests that approximately 15 to 20 patients of a given immunological class is sufficient to distinguish LT or ST CTCL surviving patients from normal controls. Two power analyses were conducted to determine whether this number of samples is adequate when trying to distinguish classes of PBMC derived from different tumors or from healthy donors. Genes with differential expression between classes ranging from 2.5 to 14 fold were chosen. The number of samples required to distinguish the two classes with equal numbers of each class was analyzed based on published microarray determinations of gene expression levels on a training set of high tumor burden (>60% tumor cells) and a validation set of low tumor burden (5-55% tumor cells) patients. These calculations apply equally to expression levels based on Real time PCR in a clinical setting.

E. Direct Enumeration.

New datasets of increasing but equal numbers of randomly selected patients and controls were created from a dataset of 16 patients and 12 controls. The probability of differential expression between the groups for each number of patients was calculated. This was repeated 100 times. For each gene, the lowest number of patients and controls were found which gave differential expression at $p < 0.05$ in at least 95 of the 100 permutations.

EXAMPLE 10: LIGANDS TO PLASTIN TISSUE 3 (PLS3)

A. Peptide Synthesis

The PLS3 specific peptides Ser-Lys-Asp-Glu-Leu-Asp-Glu-Leu-Lys-Glu-Ala-Phe-Ala-Lys (amino acids 7-20 of SEQ ID NO:1) and Arg-Glu-Ile-Ile-Gln-Lys-Leu-Met-Leu-Asp-Gly-Asp-Arg-Asn-Lys-Asp (amino acids 51-66 of SEQ ID NO:1) were synthesized using Fmoc solid phase chemistry on an automated 72-column peptide synthesizer on a 20 mg scale. These PLS3 specific peptides were purified by high performance liquid chromatography (HPLC). The peptides were conjugated to keyhole limpet hemocyanin (KLH) carrier via the branched lysine side chain.

B. Immunization of Rabbits

The peptides were emulsified with Freund's complete adjuvant (CFA) (*Antibodies - A Laboratory Manual*, Eds. E. Harlow and P. Lane, Cold Spring Harbor

Laboratory 1998). Four rabbits were injected subcutaneously on day 1 with 0.25 mg of peptide coupled to KLH (2 rabbits/peptide).

Rabbits were boosted via the same route with 0.10 mg conjugated peptide in CFA on days 14, 42, and 56 with KLH conjugate in CFA. Rabbits were bled on days 28, 56, and 70 after the respective booster injections and the serum isolated from each bleeding.

ELISAs were performed after all samples were collected and antibody titers to the injected peptides were determined. The animals were boosted one additional time and the rabbits bled again.

The sera from all bleedings for each peptide were pooled and polyclonal antibodies were purified using peptide-conjugated affinity columns.

These PLS3 specific antibodies can be used to identify CTCL T-cells using FACS analysis and immunohistochemistry. For example, a useful assay includes using a fluorescently-labeled antibody to the CD4 T-cell marker, as CTCL cells are primarily of this type, or the CD3 marker which is common to all T-cells in conjunction with PLS3 antibody, which can be visualized with a different fluorescent tag. The inclusion of a marker for the T-cell helps to differentiate the tissue cells and the T-cells of interest. Identification of T-cells that express PLS3 which is normally never expressed in lymphoid cells indicates the presence of cancer cells.

Such a diagnostic assay is useful for both Sezary Syndrome the leukemic form of CTCL and the more common Mycosis Fungoides, which is associated with the skin. For example, in an assay for MF, T-cells are eluted from a skin biopsy for testing or the assay for T-cell may be done *in situ* in the biopsy using immunofluorescent microscopy. The latter approach may be more difficult as non-lymphoid cells will normally express PLS3.

Each and every patent, patent application, and publication, including websites cited herein is hereby incorporated herein by reference in its entirety. While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention are devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims include such embodiments and equivalent variations.

CLAIMS:

1. A method of developing a gene expression profile indicative of the presence or stage of a selected a disease, disorder or genetic pathology in a mammalian subject comprising:

generating a first array of expression levels of a plurality of genes obtained from a biological sample of a subject having said disease, disorder or genetic pathology, wherein said sample contains immune cells or cancer cells, by analyzing expression of said genes in comparison to expression of said genes from a healthy subject;

applying penalized discriminant analysis to said first array by comparison to a second array of expression levels of a plurality of genes obtained from a biological sample of a healthy control or a from disease control having a different disease, disorder or genetic pathology;

applying recursive feature elimination to said first array to identify and eliminate the least informative up-regulated and down-regulated genes from said comparison;

optionally repeating said analysis and elimination steps to obtain a gene expression profile containing a statistically significant number of genes that vary in expression from the expression thereof in the array of said healthy or disease control,

wherein said gene expression profile is a characteristic of said selected disease, disorder or genetic pathology or a stage of said selected disease, disorder or genetic pathology.

2. The method according to claim 1, wherein said disease is a cancer.

3. The method according to claim 1, wherein said sample is peripheral blood.

4. The method according to claim 1, wherein said immune cells are peripheral blood mononuclear cells.

5. The method according to claim 2, wherein said cancer is characterized by a solid tumor.

6. The method according to claim 2, wherein said cancer is characterized by cancer cells in the peripheral blood.
7. The method according to claim 1, wherein said statistically significant number of genes in said profile ranges from 1 to 100 genes.
8. The method according to claim 1, wherein said statistically significant number of genes in said profile is from 2 to 10 genes.
9. The method according to claim 1, wherein said statistically significant number of genes in said profile is from 20 to 40 genes.
10. The method according to claim 1, wherein said statistically significant number of genes in said profile is between 50 to 100 genes.
11. The method according to claim 1, wherein said analysis further comprises evaluating said gene expression using shrunken centroid analysis.
12. A gene expression profile indicative of the presence or stage of a selected a disease, disorder or genetic pathology in a mammalian subject generated by the method of claim 1.
13. A gene expression profile indicative of the presence or stage of CTCL comprising expression levels of a statistically significant number of genes selected from the genes encoding PLS3, STAT4, TRAIL, CD26, RhoB, GATA3, TNFRSF5, SCYA2, PF4, CSPG2, S100A12, KLF4, ARHB, KAL1, JUNB, DUSP1, ITGB1, TOB1, GS3955, IL11RA, Clorf29, MNDA, CD1D, CX3CR1, DTR, RPA3, MADH7, CD79A, PLAU, SEC61G, and SCYA4.
14. A gene expression profile indicative of the presence or stage of a solid tumor cancer comprising expression levels of a statistically significant number of genes

selected from the genes encoding PTMA, HNRPA1, RPL41, SERPINB6, TACC1, CX3CR1, and HNRPA2B1, ACTR1A, ARPC3, WASF2, SMARCA5, ACTB ARPC4, MYO1F, LDHA, LDHB, ATP5G3, NIMA, CCNF, CDC25A, CDC25B, FCGR3A, GNLY, PRF1, CD8A, CD2, IS2RG, GZMK, ITGAM, PFN1, TIA1, GZMB, and IL2RB.

15. A method of diagnosing or staging a disease, disorder or genetic pathology in a mammalian subject comprising:

comparing the expression of a statistically significant number of genes obtained from a biological sample of said subject containing immune cells or cancer cells and comparing same to a gene expression profile characteristic of said selected disease, disorder or genetic pathology or a stage of said selected disease, disorder or genetic pathology and a gene expression profile from a similar biological sample of a healthy subject; and

detecting a variance in the expression of genes in said patient sample from those of said gene expression profiles, wherein variance in expression of said genes compared to a normal control and similarity to the characteristic gene expression profile correlates with the type and/or location of said disease, disorder or genetic pathology.

16. The method according to claim 15, wherein said statistically significant number of genes is 1 gene, said gene encodes PLS3, and said selected disease is a CTCL.

17. The method according to claim 15, wherein said statistically significant number of genes is at least 2 genes selected from the group consisting of STAT4, PLS3, TRAIL, CD26 and RhoB, wherein decreased level of STAT4 or CD26 or increased level of PL3, TRAIL or Rho B as compared to a control is indicative of a CTCL.

18. The method according to claim 17, wherein said statistically significant number of genes is at least 4 genes of said group.

19. The method according to claim 15, wherein said statistically significant genes are selected from the group consisting of GATA3, TNFRSF5, SCYA2, PF4, CSPG2, S100A15, KLF4, ARHB, KAL1, JUNB, DUSP1, ITGB1, TOB1, GS3955, IL11RA, Clorf29, MNDA, CD1D, CX3CR1, DTR, RPA3, MADH7, CD79A, PLAU, SEC61G, and SCYA4, and wherein said cancer is CTCL.

20. The method according to claim 15, wherein said statistically significant genes are selected from the group consisting of PTMA, HNRPA1, RPL41, SERPINB6, TACC1, CX3CR1, and HNRPA2B1, ACTR1A, ARPC3, WASF2, SMARCA5, ACTB, ARPC4, MYO1F, LDHA, LDHB, ATP5G3, NIMA, CCNF, CDC25A, CDC25B, FCGR3A, GNLY, PRF1, CD8A, CD2, IS2RG, GZMK, ITGAM, PFN1, TIA1, GZMB, and IL2RB, and wherein said disease is cancer characterized by a solid tumor.

21. The method according to claim 15, wherein said statistically significant genes are selected from the group consisting of cathepsin C; TIA1 cytotoxic granule-associated RNA binding protein; interleukin 2 receptor β ; Fc fragment of IgG, low affinity IIIa, receptor for CD16; granzyme B granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1; CD2 antigen p50, sheep red blood cell receptor; CD8 antigen, alpha polypeptide p32; integrin, alpha M complement component receptor 3 α ; perforin, mRNA sequence; granzyme K serine protease, granzyme 3; tryptase II; profilin 1; interleukin 2 receptor, gamma severe combined immunodeficiency; and granulysin, and wherein said disease is cancer is characterized by a solid tumor.

22. A method of identifying the effects of a therapeutic agent or treatment regimen on a patient having a cancer, said method comprising:

- (a) administering said therapeutic agent or treatment regimen to said patient;
- (b) periodically during and after administration of said agent or regimen examining a sample containing immune cells of said subject to obtain a patient expression profile of a statistically significant number of genes; and

(c) comparing said profile (b) to the same profile obtained from the patient prior to said administration and optionally to an characteristic disease profile or healthy control profile,

wherein a variance in expression of said genes in profile (b) from said prior profile or said control indicates the level of efficacy of said agent or regimen.

23. A method of identifying a cancer therapeutic agent or treatment regimen useful for the treatment of a cancer, said method comprising:

(a) administering said therapeutic agent or treatment regimen to a test mammalian subject;

(b) periodically during and after administration of said agent or regimen examining a sample containing immune cells of said subject to obtain an expression profile of a statistically significant number of genes therein; and

(c) comparing said profile (b) to the same profile obtained from the subject prior to said administration and optionally to a characteristic disease profile or a healthy control profile;

wherein a variance in expression of said genes in profile (b) from said prior profile, which variance is closer to the profile of said normal control indicates that said agent or regimen is a desirable cancer therapeutic for said cancer.

24. A method of identifying a cancer therapeutic agent or treatment regimen useful for the treatment of a cancer in an individual patient, said method comprising:

(a) examining a sample containing immune cells of said patient and obtaining an expression profile of a statistically significant number of genes therein;

(b) comparing said profile (a) to the same profile obtained from the subject prior to treatment and optionally to a characteristic disease profile or a healthy control profile, or to at least one or an average of immune cell gene expression profiles obtained from other subjects previously successfully treated for the same cancer with a selected agent or regimen;

wherein similarities in said profile of said patient with one of said average profiles is indicative that said agent or regimen used for subjects from said average profile is a desirable cancer therapeutic or regimen for said patient.

25. A method for diagnosing or staging a cutaneous T cell lymphoma (CTCL) comprising detecting in a sample the level of at least two genes comprising of the following: STAT4, PLS3, TRAIL, CD26 or RhoB, wherein decreased level of STAT4 or CD26 or increased level of PL3, TRAIL or Rho B as compared to a control is indicative of a CTCL.
26. The method according to claim 25, further comprising preparing an expression profile of at least four said genes.
27. The method according to claim 26, further comprising preparing an expression profile of all five said genes.
28. The method according to claim 26, further comprising detecting the level or profile of expression of a gene expressed from the group consisting of GATA3, TNFRSF5, SCYA2, PF4, CSPG2, S100A12, KLF4, ARHB, KAL1, JUNB, DUSP1, ITGB1, TOB1, GS3955, IL11RA, Clorf29, MNDA, CD1D, CX3CR1, DTR, RPA3, MADH7, CD79A, PLAUI, SEC61G, and SCYA4, and combinations thereof.
29. A method of staging a cutaneous T cell lymphoma (CTCL) comprising detecting in a sample the level of at least one of the following: ILR2B, TGFBR3, BCL2, TCN1, SFTPD, P4HB, LY64, HEHU, DAD1, or BATF, wherein an increased level of or increased level of ILR2B, TGFBR3, BCL2, TCN1, SFTPD, P4HB, LY64, HEHU, DAD1, or BATF as compared to a control is indicative of the stage of a CTCL.
30. The method according to claim 29, further comprising detecting the level or expression profile of a protein selected from the group consisting of HLA-DQB1, ITIH4, PGDS, ACRB2, ICSBP1, TCL1A, PDCD2, CHK, HLA-DMB, CDR2 EIF2B5, CD1D, PGRMC1, FGF12B, TRA1, RPA3, RAD23B, FLJ32496, BAZ, CCND2, NRP2, ENG, HSP#1, FKBP5, PASK, IL9, TEAD4, AR, RARB, and RPIA, and a combination thereof.

31. A method for selecting a therapeutic regimen for treatment of CTCL comprising detecting in a sample the level of at least one of the following: IL2RB, CD1D, DAD1, BAX, AR, SIRT5 or RARB; comparing said level to a control wherein said comparative level is indicative of a therapeutic regimen for treatment of CTCL.
32. A non-naturally occurring or purified ligand that specifically binds to an epitope sequence located within a peptide or polypeptide
Ser-Lys-Asp-Glu-Leu-Asp-Glu-Leu-Lys-Glu-Ala-Phe-Ala-Lys (amino acids 7-20 of SEQ ID NO:1) or which specifically binds to a nucleic acid sequence encoding said peptide or polypeptide.
33. The ligand according to claim 32, which is an antibody, optionally associated with a detectable label or protein.
34. The ligand according to claim 33, wherein said protein is a therapeutic protein.
35. A non-naturally occurring or purified ligand that binds to an epitope sequence located within a peptide or polypeptide
Arg-Glu-Ile-Ile-Gln-Lys-Leu-Met-Leu-Asp-Gly-Asp-Arg-Asn-Lys-Asp (amino acids 51-66 of SEQ ID NO:1) or which specifically binds to a nucleic acid sequence encoding said peptide or polypeptide.
36. The ligand according to claim 35, which is an antibody, optionally associated with a detectable label or protein.
37. The ligand according to claim 36, wherein said protein is a therapeutic protein.
38. A method for diagnosing CTCL comprising detecting in a sample of lymphoid cells from a human subject the expression of a PLS3 gene, wherein said presence of said gene in lymphoid cells is indicative of a CTCL.

39. The method according to claim 38, wherein said detecting comprises contacting said sample with a ligand that specifically binds an epitope present in the tissue plastin member of the plastin gene family, said ligand associated with a detectable label; and detecting bound protein in said sample.

40. The method according to claim 39, wherein said ligand is a non-naturally occurring or purified ligand that binds to an epitope within the sequence of Ser-Lys-Asp-Glu-Leu-Asp-Glu-Leu-Lys-Glu-Ala-Phe-Ala-Lys (amino acids 7-20 of SEQ ID NO:1) or Arg-Glu-Ile-Ile-Gln-Lys-Leu-Met-Leu-Asp-Gly-Asp-Arg-Asn-Lys-Asp (amino acids 51-65 of SEQ ID NO:1) or which specifically binds to a nucleic acid sequence encoding said peptides or polypeptides.

41. A kit for diagnosis of CTCL in a mammalian patient comprising a ligand that specifically binds to tissue plastin protein PLS3 and a detectable label.

42. The kit according to claim 41, wherein said ligand is a non-naturally occurring or purified ligand that binds to an epitope within the sequence of Ser-Lys-Asp-Glu-Leu-Asp-Glu-Leu-Lys-Glu-Ala-Phe-Ala-Lys (amino acids 7-20 of SEQ ID NO:1) or Arg-Glu-Ile-Ile-Gln-Lys-Leu-Met-Leu-Asp-Gly-Asp-Arg-Asn-Lys-Asp (amino acids 51-65 of SEQ ID NO:1) or which specifically binds to a nucleic acid sequence encoding said peptides or polypeptides.

43. A diagnostic kit containing a characteristic gene expression profile for a selected disease prepared by the method of claim 1.




Fig. 1B

Fig. 1A

2/18




Fig. 2A

BEST AVAILABLE COPY

3/18




Fig. 2B

BEST AVAILABLE COPY




Fig. 3

5/18




Fig. 4A

BEST AVAILABLE COPY

6/18




Fig. 4B

BEST AVAILABLE COPY




Fig. 5




Fig. 6

9/18




Fig. 7





Fig. 8






Fig. 10




Fig. 11




Fig. 12

15/18




Fig. 13




Fig. 14




Fig. 15




Fig. 16

SEQUENCE LISTING

- <110> The Wistar Institute of Anatomy and Biology
 Showe, Louise C.
 Showe, Michael K.
 Kari, Laszlo
 Nebozhyn, Michael
 Loboda, Andrey
- <120> Method of Diagnosis of Cancer Based on Gene Expression Profiles
 in Cells
- <130> WST114APCT
- <150> US 60/472,173
 <151> 2003-05-21
- <150> US 60/506,042
 <151> 2003-09-25
- <160> 87
- <170> PatentIn version 3.2
- <210> 1
 <211> 627
 <212> PRT
 <213> human plastin T protein
- <400> 1

Met Ala Thr Thr Gln Ile Ser Lys Asp Glu Leu Asp Glu Leu Lys Glu
 1 5 10 15

Ala Phe Ala Lys Val Asp Leu Asn Ser Asn Gly Phe Ile Cys Asp Tyr
 20 25 30

Glu Leu His Glu Leu Phe Lys Glu Ala Asn Met Pro Leu Pro Gly Tyr
 35 40 45

Lys Val Arg Glu Ile Ile Gln Lys Leu Met Leu Asp Gly Asp Arg Asn
 50 55 60

Lys Asp Gly Lys Ile Ser Phe Asp Glu Phe Val Tyr Ile Phe Gln Glu
 65 70 75 80

Val Lys Ser Ser Asp Ile Ala Lys Thr Phe Arg Lys Ala Ile Asn Arg
 85 90 95

Lys Glu Gly Ile Cys Ala Leu Gly Gly Thr Ser Glu Leu Ser Ser Glu
 100 105 110

Gly Thr Gln His Ser Tyr Ser Glu Glu Glu Lys Tyr Ala Phe Val Asn
 115 120 125

Trp Ile Asn Lys Ala Leu Glu Asn Asp Pro Asp Cys Arg His Val Ile
 130 135 140

Pro Met Asn Pro Asn Thr Asp Asp Leu Phe Lys Ala Val Gly Asp Gly
 145 150 155 160

Ile Val Leu Cys Lys Met Ile Asn Leu Ser Val Pro Asp Thr Ile Asp
 165 170 175
 Glu Arg Ala Ile Asn Lys Lys Lys Leu Thr Pro Phe Ile Ile Gln Glu
 180 185 190
 Asn Leu Asn Leu Ala Leu Asn Ser Ala Ser Ala Ile Gly Cys His Val
 195 200 205
 Val Asn Ile Gly Ala Glu Asp Leu Arg Ala Gly Lys Pro His Leu Val
 210 215 220
 Leu Gly Leu Leu Trp Gln Ile Ile Lys Ile Gly Leu Phe Ala Asp Ile
 225 230 235 240
 Glu Leu Ser Arg Asn Glu Ala Leu Ala Ala Leu Leu Arg Asp Gly Glu
 245 250 255
 Thr Leu Glu Glu Leu Met Lys Leu Ser Pro Glu Glu Leu Leu Leu Arg
 260 265 270
 Trp Ala Asn Phe His Leu Glu Asn Ser Gly Trp Gln Lys Ile Asn Asn
 275 280 285
 Phe Ser Ala Asp Ile Lys Asp Ser Lys Ala Tyr Phe His Leu Leu Asn
 290 295 300
 Gln Ile Ala Pro Lys Gly Gln Lys Glu Gly Glu Pro Arg Ile Asp Ile
 305 310 315 320
 Asn Met Ser Gly Phe Asn Glu Thr Asp Asp Leu Lys Arg Ala Glu Ser
 325 330 335
 Met Leu Gln Gln Ala Asp Lys Leu Gly Cys Arg Gln Phe Val Thr Pro
 340 345 350
 Ala Asp Val Val Ser Gly Asn Pro Lys Leu Asn Leu Ala Phe Val Ala
 355 360 365
 Asn Leu Phe Asn Lys Tyr Pro Ala Leu Thr Lys Pro Glu Asn Gln Asp
 370 375 380
 Ile Asp Trp Thr Leu Leu Glu Gly Glu Thr Arg Glu Glu Arg Thr Phe
 385 390 395 400
 Arg Asn Trp Met Asn Ser Leu Gly Val Asn Pro His Val Asn His Leu
 405 410 415
 Tyr Ala Asp Leu Gln Asp Ala Leu Val Ile Leu Gln Leu Tyr Glu Arg
 420 425 430

Ile Lys Val Pro Val Asp Trp Ser Lys Val Asn Lys Pro Pro Tyr Pro
435 440 445

Lys Leu Gly Ala Asn Met Lys Lys Leu Glu Asn Cys Asn Tyr Ala Val
450 455 460

Glu Leu Gly Lys His Pro Ala Lys Phe Ser Leu Val Gly Ile Gly Gly
465 470 475 480

Gln Asp Leu Asn Asp Gly Asn Gln Thr Leu Thr Leu Ala Leu Val Trp
485 490 495

Gln Leu Met Arg Arg Tyr Thr Leu Asn Val Leu Glu Asp Leu Gly Asp
500 505 510

Gly Gln Lys Ala Asn Asp Asp Ile Ile Val Asn Trp Val Asn Arg Thr
515 520 525

Leu Ser Glu Ala Gly Lys Ser Thr Ser Ile Gln Ser Phe Lys Asp Lys
530 535 540

Thr Ile Ser Ser Ser Leu Ala Val Val Asp Leu Ile Asp Ala Ile Gln
545 550 555 560

Pro Gly Cys Ile Asn Tyr Asp Leu Val Lys Ser Gly Asn Leu Thr Glu
565 570 575

Asp Asp Lys His Asn Asn Ala Lys Tyr Ala Val Ser Met Ala Arg Arg
580 585 590

Ile Gly Ala Arg Val Tyr Ala Leu Pro Glu Asp Leu Val Glu Val Lys
595 600 605

Pro Lys Met Val Met Thr Val Phe Ala Cys Leu Met Gly Arg Gly Met
610 615 620

Lys Arg Val
625

<210> 2
<211> 21
<212> DNA
<213> Artificial

<220>
<223> SF3A1 primer

<400> 2
ggataagacg gaatgaaac t

21

<210> 3
<211> 18
<212> DNA
<213> Artificial

<220>
<223> SF3A1 primer
<400> 3
aatggcaggg acttgaca 18

<210> 4
<211> 24
<212> DNA
<213> Artificial

<220>
<223> CCT3 primer
<400> 4
agctgggaca gaaagaaagg gact 24

<210> 5
<211> 20
<212> DNA
<213> Artificial

<220>
<223> CCT3 primer
<400> 5
aacagtggaa gacggcagtt 20

<210> 6
<211> 18
<212> DNA
<213> Artificial

<220>
<223> GATA3 primer
<400> 6
tatccatcgc gtttaggc 18

<210> 7
<211> 19
<212> DNA
<213> Artificial

<220>
<223> GATA3 primer
<400> 7
cccaagaaca gctcgttta 19

<210> 8
<211> 18
<212> DNA
<213> Artificial

<220>
<223> ARI03 primer
<400> 8
ataggcccca atacttgt 18

<210> 9

<211> 19
<212> DNA
<213> Artificial

<220>
<223> ARI03 primer

<400> 9
acacttaatg cactcgtca 19

<210> 10
<211> 17
<212> DNA
<213> Artificial

<220>
<223> DUSPI primer

<400> 10
tgaaggcaga cacctac 17

<210> 11
<211> 18
<212> DNA
<213> Artificial

<220>
<223> DUSPI primer

<400> 11
gcacattcgg gaccaata 18

<210> 12
<211> 18
<212> DNA
<213> Artificial

<220>
<223> PLS3 primer

<400> 12
gcttgacaaa gcaagagt 18

<210> 13
<211> 19
<212> DNA
<213> Artificial

<220>
<223> PLS3 primer

<400> 13
gcattctccc tctcatacc 19

<210> 14
<211> 20
<212> DNA
<213> Artificial

<220>
<223> CDSIW primer

<400> 14
ccctgctata cataaagggtg 20

<210>	15
<211>	22
<212>	DNA
<213>	Artificial

<220>
<223> CDSIW primer

<400> 15
gcttgtgaga ttgagaatga ac 22

<210>	16
<211>	18
<212>	DNA
<213>	Artificial

<220>
<223> ISGI5 primer

<400> 16
gcttgaggcc gtactccc 18

<210>	17
<211>	20
<212>	DNA
<213>	Artificial

<220>
<223> ISGI5 primer

<400> 17
 caaatgcgac gaacctctga 20

<210>	18
<211>	20
<212>	DNA
<213>	Artificial

<220>
<223> ITGB1 primer

<400> 18
gcttccatat cagcagtaat 20

<210>	19
<211>	19
<212>	DNA
<213>	Artificial

<220>
<223> ITGB1 primer

```
<400> 19
gtagaaagtc gggacaaat 19
```

<210>	20
<211>	17
<212>	DNA
<213>	Artificial

<220>
<223> CDKN2 primer

<400> 20
dctgctgaag caaggtg 17

<210> 21
<211> 18
<212> DNA
<213> Artificial

<220>
<223> CDKN2 primer

<400> 21
cagtgtgacc ctcttgaa 18

<210> 22
<211> 21
<212> DNA
<213> Artificial

<220>
<223> CCR1 primer

<400> 22
gggtaaatgg aaatgatgag t 21

<210> 23
<211> 21
<212> DNA
<213> Artificial

<220>
<223> CCR1 primer

<400> 23
gagttgagac ctaacgagaa a 21

<210> 24
<211> 21
<212> DNA
<213> Artificial

<220>
<223> JUNB primer

<400> 24
actctttaga gactaagtgc g 21

<210> 25
<211> 18
<212> DNA
<213> Artificial

<220>
<223> JUNB primer

<400> 25
ccacctcgac gtttataa 18

<210> 26
<211> 23
<212> DNA
<213> Artificial

<220>
<223> CYPTB1 primer
<400> 26
ttggtatatc aaacagtaaa ggc 23

<210> 27
<211> 19
<212> DNA
<213> Artificial

<220>
<223> CYPTB1 primer
<400> 27
tcatgtccca gaacttagc 19

<210> 28
<211> 25
<212> DNA
<213> Artificial

<220>
<223> STAT2 primer
<400> 28
tcctagaacc tggatattta caaag 25

<210> 29
<211> 17
<212> DNA
<213> Artificial

<220>
<223> STAT2 primer
<400> 29
gtgtatgccg gtgttga 17

<210> 30
<211> 20
<212> DNA
<213> Artificial

<220>
<223> ARIIGEF6 primer
<400> 30
tgctctcaga ttaacatggc 20

<210> 31
<211> 24
<212> DNA
<213> Artificial

<220>
<223> ARIIGEF6 primer
<400> 31
ggaatacttt agttgattgc tgaa 24

<210> 32

<211> 20
 <212> DNA
 <213> Artificial

<220>
 <223> SELL primer

<400> 32
 ctcacatcatgg gttggattag

20

<210> 33
 <211> 19
 <212> DNA
 <213> Artificial

<220>
 <223> SELL primer

<400> 33
 ctgcaagtga catctcttt

19

<210> 34
 <211> 21
 <212> DNA
 <213> Artificial

<220>
 <223> CDSA primer

<400> 34
 ataacagcat agtacaaccc t

21

<210> 35
 <211> 19
 <212> DNA
 <213> Artificial

<220>
 <223> CDSA primer

<400> 35
 gtatggtaca agcaatgcc

19

<210> 36
 <211> 18
 <212> DNA
 <213> Artificial

<220>
 <223> DPPS primer

<400> 36
 ttgaattatc cggtcggg

18

<210> 37
 <211> 18
 <212> DNA
 <213> Artificial

<220>
 <223> DPPS primer

<400> 37
 cctggctgtg ttggtatg

18

<210> 38
<211> 21
<212> DNA
<213> Artificial

<220>
<223> PPIA primer

<400> 38
cgtaaaccct ggaataattc t 21

<210> 39
<211> 19
<212> DNA
<213> Artificial

<220>
<223> PPIA primer

<400> 39
ctgtgtctcc ttcgagta 19

<210> 40
<211> 22
<212> DNA
<213> Artificial

<220>
<223> ZNF161 primer

<400> 40
caggtcacaa tccctattat ac 22

<210> 41
<211> 18
<212> DNA
<213> Artificial

<220>
<223> ZNF161 primer

<400> 41
acactagcag gactcttc 18

<210> 42
<211> 22
<212> DNA
<213> Artificial

<220>
<223> SOD1 primer

<400> 42
ccacataata agtgccatac ag 22

<210> 43
<211> 23
<212> DNA
<213> Artificial

<220>
<223> SOD1 primer

<400> 43
ccttaaaagt gtaattgtgt gtc

23

<210> 44
<211> 20
<212> DNA
<213> Artificial

<220>
<223> ICAM2 primer

<400> 44
agaaggtatt cgaggtacac

20

<210> 45
<211> 16
<212> DNA
<213> Artificial

<220>
<223> ICAM2 primer

<400> 45
gtacacgctg acgttg

16

<210> 46
<211> 21
<212> DNA
<213> Artificial

<220>
<223> TNFRST6 primer

<400> 46
acgtctgttg ctagattatc g

21

<210> 47
<211> 16
<212> DNA
<213> Artificial

<220>
<223> TNFRST6 primer

<400> 47
cacgcagtct ggttca

16

<210> 48
<211> 19
<212> DNA
<213> Artificial

<220>
<223> TNFST6 primer

<400> 48
aaggtctaca tgaggaact

19

<210> 49
<211> 17
<212> DNA
<213> Artificial

<220>
<223> TNFST6 primer

<400> 49
agccgaaaaa cgtctga 17

<210> 50
<211> 16
<212> DNA
<213> Artificial

<220>
<223> LCP1 primer

<400> 50
atagaggcg tcttgc 16

<210> 51
<211> 18
<212> DNA
<213> Artificial

<220>
<223> LCP1 primer

<400> 51
ctcacataca cacacacc 18

<210> 52
<211> 19
<212> DNA
<213> Artificial

<220>
<223> ILI8 primer

<400> 52
ggatgaattg ggggataga 19

<210> 53
<211> 21
<212> DNA
<213> Artificial

<220>
<223> ILI8 primer

<400> 53
gtcactacac tcagctaatt t 21

<210> 54
<211> 20
<212> DNA
<213> Artificial

<220>
<223> TNFRST5 primer

<400> 54
cactatcaca aacaatgctg 20

<210> 55

<211> 19
<212> DNA
<213> Artificial

<220>
<223> TNFRST5 primer

<400> 55
accttgaaga acctctcac 19

<210> 56
<211> 21
<212> DNA
<213> Artificial

<220>
<223> TNFST5 primer

<400> 56
tatacactcc aaggcatgta g 21

<210> 57
<211> 18
<212> DNA
<213> Artificial

<220>
<223> TNFST5 primer

<400> 57
ctccccattt cccttctg 18

<210> 58
<211> 17
<212> DNA
<213> Artificial

<220>
<223> MGAM primer

<400> 58
attattcctc ccaccgc 17

<210> 59
<211> 17
<212> DNA
<213> Artificial

<220>
<223> MGAM primer

<400> 59
tgaactgggt ccatgat 17

<210> 60
<211> 19
<212> DNA
<213> Artificial

<220>
<223> CD44 primer

<400> 60
atgggttatgt ttccaacgg 19

<210> 61
<211> 18
<212> DNA
<213> Artificial

<220>
<223> CD44 primer

<400> 61
gtggactcaa cggagagg

18

<210> 62
<211> 20
<212> DNA
<213> Artificial

<220>
<223> NFKDIA primer

<400> 62
gtacagcatt tacaggaggg

20

<210> 63
<211> 17
<212> DNA
<213> Artificial

<220>
<223> NFKDIA primer

<400> 63
ctcaccttg tgggggtt

17

<210> 64
<211> 19
<212> DNA
<213> Artificial

<220>
<223> NFKB1 primer

<400> 64
tacaggtcca gggatatgc

19

<210> 65
<211> 20
<212> DNA
<213> Artificial

<220>
<223> NFKB1 primer

<400> 65
gctctgtggt ttcaataact

20

<210> 66
<211> 18
<212> DNA
<213> Artificial

<220>
<223> MB04 primer

<400> 66
cacatctctc cagtctgc 18

<210> 67
<211> 20
<212> DNA
<213> Artificial

<220>
<223> MBO4 primer

<400> 67
cgacgtaaag cctttaagaa 20

<210> 68
<211> 17
<212> DNA
<213> Artificial

<220>
<223> CDID primer

<400> 68
tgagacgcct ctgtttc 17

<210> 69
<211> 22
<212> DNA
<213> Artificial

<220>
<223> CDID primer

<400> 69
acacctcaaa tacataccta ct 22

<210> 70
<211> 21
<212> DNA
<213> Artificial

<220>
<223> CX3CRI primer

<400> 70
agtaatggca agtaaattgg g 21

<210> 71
<211> 19
<212> DNA
<213> Artificial

<220>
<223> CX3CRI primer

<400> 71
caaatagtc tcgctttct 19

<210> 72
<211> 18
<212> DNA
<213> Artificial

<220>
<223> ILIR2 primer
<400> 72
aggacacagc ggtaatag 18

<210> 73
<211> 17
<212> DNA
<213> Artificial

<220>
<223> ILIR2 primer
<400> 73
ccattgagcc tcagagt 17

<210> 74
<211> 19
<212> DNA
<213> Artificial

<220>
<223> I%FSFIO primer
<400> 74
acgtgtactt taccaacga 19

<210> 75
<211> 16
<212> DNA
<213> Artificial

<220>
<223> I%FSFIO primer
<400> 75
atgccactc cttgat 16

<210> 76
<211> 22
<212> DNA
<213> Artificial

<220>
<223> ILIRI primer
<400> 76
atggctcaat accttttatt gc 22

<210> 77
<211> 21
<212> DNA
<213> Artificial

<220>
<223> ILIRI primer
<400> 77
aaaactttta atgccttcca c 21

<210> 78

<211> 18
<212> DNA
<213> Artificial

<220>
<223> GATA3 primer

<400> 78
tatccatcgc gtttaggc 18

<210> 79
<211> 19
<212> DNA
<213> Artificial

<220>
<223> GATA3 primer

<400> 79
cccaagaaca gctcgttta 19

<210> 80
<211> 18
<212> DNA
<213> Artificial

<220>
<223> PLS3 primer

<400> 80
gcttgacaaa gcaagagt 18

<210> 81
<211> 19
<212> DNA
<213> Artificial

<220>
<223> PLS3 primer

<400> 81
gcatcttccc tctcatacc 19

<210> 82
<211> 25
<212> DNA
<213> Artificial

<220>
<223> STAT4 primer

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is a, c, g, or t

<400> 82
tcctagaacc tggntattta caaag 25

<210> 83
<211> 17
<212> DNA
<213> Artificial

<220>
<223> STAT4 primer

<400> 83
gtgtatgccg gtgttga

<210> 84
<211> 17
<212> DNA
<213> Artificial

<220>
<223> CD1D primer

<400> 84
tgagacgcct ctgtttc

<210> 85
<211> 22
<212> DNA
<213> Artificial

<220>
<223> CD1D primer

<400> 85
acacctcaaa tacataccta ct

<210> 86
<211> 19
<212> DNA
<213> Artificial

<220>
<223> TRAIL primer

<400> 86
acgtgtactt taccaacga

<210> 87
<211> 16
<212> DNA
<213> Artificial

<220>
<223> TRAIL primer

<400> 87
atgcccactc cttgat

17

17

22

19

16